MusclePharm (MSLPQ) 10-Q 5 Aug 14 2014 Q2 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 01, 2014
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Entity Registrant Name	'MusclePharm Corp	'
Entity Central Index Key	'0001415684	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'MSLP	'
Entity Common Stock, Shares Outstanding	'	11,128,440

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Cash	$3,768,840	$5,411,515
Cash - restricted	0	2,500,014
Investment in debt securities	0	259,715
Accounts receivable - net of allowance for doubtful accounts	19,197,544	13,741,180
Derivative instrument	0	119,248
Inventory - net	19,769,356	15,772,368
Prepaid giveaways	975,450	1,177,539
Prepaid stock compensation	3,018,940	3,023,717
Prepaid sponsorship and endorsement fees	151,892	1,145,161
Prepaid expenses	1,989,597	1,335,218
Other receivable	1,342,843	0
Other assets	333,240	40,805
Total current assets	50,547,702	44,526,480
Property and equipment - net	6,221,261	2,613,584
Intangible assets - net	6,732,532	155,165
Prepaid stock compensation	3,251,791	4,718,238
Other assets	179,632	144,229
Total assets	66,932,918	52,157,696
Current liabilities:	'	'
Accounts payable	23,900,432	26,605,588
Accrued liabilities	4,527,085	2,053,101
Line of credit	0	2,500,000
Notes payable	45,600	62,502
Derivative liabilities	0	1,147,330
Total current liabilities	28,473,117	32,368,521
Other long-term liabilities	366,378	54,639
Total liabilities	28,839,495	32,423,160
Commitments and Contingencies (Note 10)	'	'
Stockholders' Equity:	'	'
Common Stock, $0.001 par value; 100,000,000 shares authorized; 10,782,833 and 9,259,411 shares issued, respectively; 10,612,912 and 9,089,490 shares issued and outstanding, respectively	10,783	9,260
Additional paid-in capital	118,259,128	103,064,901
Treasury stock at cost; 169,921 shares	-1,498,298	-1,498,298
Accumulated other comprehensive income (loss)	4,665	-14,042
Accumulated deficit	-78,682,855	-81,827,417
Total stockholders' equity	38,093,423	19,734,536
Total Liabilities and Stockholders' Equity	66,932,918	52,157,696
Series D Convertible Preferred Stock [Member]	'	'
Stockholders' Equity:	'	'
Series D, Convertible Preferred Stock, $0.001 par value; 1,600,000 shares authorized; 1,500,000 shares issued; none and 131,500 shares issued and outstanding, respectively	$0	$132

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets [Parenthetical] (USD $)	Jun. 30, 2014	Dec. 31, 2013
Common Stock, par value (in dollars per share)	$0.00	$0.00
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	10,782,833	9,259,411
Common Stock, shares outstanding	10,612,912	9,089,490
Treasury Stock, shares	169,921	169,921
Series D Convertible Preferred Stock [Member]	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	1,600,000	1,600,000
Preferred stock, shares issued	1,500,000	1,500,000
Preferred stock, shares outstanding	0	131,500

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Sales - net	$46,739,987	$25,480,059	$96,949,441	$48,041,226
Cost of sales	31,093,224	17,566,718	63,429,609	31,963,124
Gross profit	15,646,763	7,913,341	33,519,832	16,078,102
Operating expenses:	'	'	'	'
Advertising and promotion	5,919,263	3,275,200	12,247,749	5,592,577
Salaries and benefits	5,777,488	1,563,909	11,144,295	2,812,368
Selling, general, and administrative	2,356,940	1,918,665	4,229,308	3,064,220
Research and development	1,163,883	169,231	2,260,829	259,361
Professional fees	-50,326	3,727,267	734,247	7,811,986
Total operating expenses	15,167,248	10,654,272	30,616,428	19,540,512
Operating income (loss)	479,515	-2,740,931	2,903,404	-3,462,410
Other income (expense), net:	'	'	'	'
Derivative expense	0	0	0	-96,913
Change in fair value of derivative liabilities	-110,289	272,681	373,944	-5,771,963
Gain on settlement of accounts payable	25,978	47,671	31,477	324,656
Interest expense	-17,015	-1,125	-56,388	-781,445
Foreign currency transaction loss	-4,390	-104	-34,496	-5,714
Loss on derivative instrument and debt security	0	0	-386,103	0
Interest income	0	0	223,049	0
Other income, net	79,315	0	166,622	10,000
Total other income (expense), net	-26,401	319,123	318,105	-6,321,379
Net income (loss) before taxes	453,114	-2,421,808	3,221,509	-9,783,789
Provision for income taxes	-44,786	0	-76,947	0
Net income (loss)	408,328	-2,421,808	3,144,562	-9,783,789
Other comprehensive income (loss)	'	'	'	'
Net change in foreign currency translation	22,954	4,228	18,707	-1,841
Total other comprehensive income (loss)	22,954	4,228	18,707	-1,841
Total comprehensive income (loss)	$431,282	($2,417,580)	$3,163,269	($9,785,630)
Net income (loss) per share:	'	'	'	'
Basic (in dollars per share)	$0.04	($0.34)	$0.30	($1.72)
Diluted (in dollars per share)	$0.03	($0.34)	$0.27	($1.72)
Weighted average number of shares used in per share calculations - Basic (in shares)	10,610,022	7,226,849	10,459,522	5,686,323
Weighted average number of shares used in per share calculations - Diluted (in shares)	12,064,122	7,226,849	11,863,882	5,686,323

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash Flows From Operating Activities:	'	'
Net income (loss)	$3,144,562	($9,783,789)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:	'	'
Depreciation of property and equipment	646,673	333,383
Bad debt	140,155	105,271
Amortization of prepaid stock compensation	1,577,882	3,345,332
Amortization of prepaid sponsorships fees	3,468,227	1,834,922
Amortization of intangible assets	578,295	0
Stock-based compensation	4,466,876	74,366
Amortization of debt issuance costs	0	335,433
Accretion of conversion option on debt security	-222,140	0
Gain on settlement of accounts payable	-31,477	-324,656
Loss on disposal of property and equipment	30,606	0
Derivative expense	0	96,913
Loss on sale of debt security and derivative instrument	386,103	0
Change in fair value of derivative liabilities	-373,944	5,771,963
Changes in operating assets and liabilities, net of acquisition:	'	'
Accounts receivable	-4,790,307	-5,713,366
Inventory	-3,155,989	-170,254
Prepaid giveaways	202,089	257,120
Prepaid assets	-3,114,827	-2,410,550
Other receivable	-1,342,843	0
Other assets	235,105	-666,618
Accounts payable	-2,664,980	80,187
Accrued liabilities	1,074,592	1,660,385
Other long-term liabilities	285,230	0
Net Cash Provided by (Used in) Operating Activities	539,888	-5,173,958
Cash Flows From Investing Activities:	'	'
Purchase of property and equipment	-2,401,182	-307,760
Change in restricted cash balance	2,500,014	9,148
Proceeds from sale of debt security	215,000	0
Proceeds from disposal of property and equipment	1,800	1,694
Purchase of trademark	0	-47,500
Net Cash Provided by (Used In) Investing Activities	315,632	-344,418
Cash Flows From Financing Activities:	'	'
Payment on line of credit	-2,500,000	0
Payment on notes payable	-16,902	-4,393,234
Stock issuance costs	0	-1,662,667
Proceeds from issuance of preferred stock	0	12,000,000
Proceeds from issuance of common stock and warrants	0	8,327,499
Repurchase of common stock (treasury stock)	0	-103,537
Net Cash (Used In) Provided by Financing Activities	-2,516,902	14,168,061
Effect of exchange rates on cash and cash equivalents	18,707	6,076
Net (decrease) increase in cash	-1,642,675	8,655,761
Cash at beginning of period	5,411,515	0
Cash at end of period	3,768,840	8,655,761
Supplemental disclosures of cash flow information:	'	'
Cash paid for interest	52,835	410,502
Cash paid for taxes	77,212	0
Supplemental disclosure of non-cash investing and financing activities:	'	'
Stock issued for future services - third parties	0	4,409,897
Warrants issued in conjunction with equity issuances	0	8,175,459
Stock issued to settle accounts payable and accrued expenses- third parties	0	5,484,947
Stock issued for Biozone acquisition	9,840,000	0
Stock issued for board compensation	115,358	114,912
Reclassification of derivative liability to additional paid in capital	773,386	0
Capital leases	$26,509	$0

Nature_of_Operations_and_Basis

Nature of Operations and Basis of Presentation	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Business Description and Basis of Presentation [Text Block]	'
	Note 1: Nature of Operations and Basis of Presentation
	MusclePharm Corporation (the “Company”) is a scientifically driven, performance lifestyle Company that develops, manufactures, markets and distributes branded nutritional supplements. The Company was incorporated in Nevada in 2006, and principal executive offices are located in Denver, Colorado.
	The accompanying interim unaudited consolidated financial statements as of June 30, 2014 and 2013, and for the three and six months then ended, have been prepared by the Company in accordance with generally accepted accounting principles (“GAAP”) in the United States (“U.S.”) for interim financial information. The amounts as of December 31, 2013 have been derived from the Company’s annual audited financial statements. In the opinion of management, the accompanying unaudited consolidated financial statements reflect all adjustments necessary (consisting of normal recurring adjustments) to state fairly the financial position of the Company and its results of operations and cash flows as of and for the periods presented. These financial statements should be read in conjunction with the annual audited financial statements and notes thereto as of and for the year ended December 31, 2013, included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013, filed on March 31, 2014 (the “Form 10-K”).
	The results of operations for the three and six months ended June 30, 2014 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2014 or any future period and the Company makes no representations related thereto.
	Reclassification
	The Company has reclassified certain prior period amounts to conform to the current period presentation. These reclassifications had no effect on the financial position, results of operations or cash flows for the periods presented.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	Note 2: Summary of Significant Accounting Policies
	Principles of Consolidation
	The consolidated financial statements include the accounts of MusclePharm Corporation and its wholly-owned subsidiaries MusclePharm Canada Enterprises Corp (“MusclePharm Canada”) and Biozone Laboratories, Inc. (“Biozone”). MusclePharm Canada began operations in April 2012 and Biozone was acquired in January 2014. All intercompany accounts and transactions have been eliminated upon consolidation.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The accounting estimates and assumptions that require management’s most significant, difficult, and subjective judgment include the recognition and measurement of allowance for doubtful accounts, inventory reserve, derivatives, and sales discounts and allowances reserve among others. Actual results experienced by the Company may differ from management’s estimates.
	Risks and Uncertainties
	The Company operates in an industry that is subject to rapid change and intense competition. The Company’s operations will be subject to significant risk and uncertainties including financial, operational, technological, regulatory, industry adverse publicity and other risks, including the potential risk of business failure.
	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board ("FASB") amended the existing accounting standards for revenue recognition. The amendments are based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. MusclePharm is required to adopt the amendments in the first quarter of 2017. Early adoption is not permitted. The amendments may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of initial application. MusclePharm is currently evaluating the impact of these amendments and the transition alternatives on its Consolidated Financial Statements.
	Cash and Cash Equivalents
	The Company considers all highly liquid instruments purchased with an original or remaining maturity of three months or less at the date of purchase to be cash equivalents At June 30, 2014 and December 31, 2013, respectively, the Company had no cash equivalents.
	The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its primary financial institution. The cash balance at times may exceed federally insured limits, and at June 30, 2014 we had one bank account that exceeded the federally insured limit, and at December 31,2013 we had two bank accounts that exceeded the federally insured limit.
	Accounts Receivable and Allowance for Doubtful Accounts
	Accounts receivable represents trade obligations from customers that are subject to normal trade collection terms. The Company’s finance department monitors the status of customer receivables and takes actions to collect past due balances as necessary. The Company periodically evaluates the collectability of its accounts receivable and considers the need to establish an allowance for doubtful accounts based upon historical collection experience and specific customer information. Accordingly, the actual amounts could vary from the recorded allowances. There is also a review of customer discounts at the period end and an accrual made for discounts earned but not yet utilized by period end.
	Management performs ongoing evaluations of the Company’s customers’ financial condition and generally does not require collateral. Some international customers are required to pay for their orders in advance of shipment. Management reviews accounts receivable quarterly and reduces the carrying amount by a valuation allowance that reflects management’s best estimate of amounts that may not be collectible. Allowances, if any, for uncollectible accounts receivable are determined based upon the aging of accounts receivable, changes in customer credit worthiness, general market and economic conditions, and historical experience. Bad debt expense recognized as a result of our valuation allowance is classified under Selling, general and administrative expense in the Consolidated Statement of Operations.
	The Company does not charge interest on past due receivables. Receivables are determined to be past due based on the payment terms of the original invoices.
	Inventory
	Inventory is valued at the lower of cost or market value. The cost of product inventory for MusclePharm and MusclePharm Canada is computed using actual cost on a First-In First-Out basis, and the cost of inventory for Biozone is computed using an average cost basis. Adjustments to reduce the cost of inventory to its net realizable value are made, if required, and estimates are made for obsolescence, excess or slow-moving inventories, non-conforming inventories, and expired inventory.
	Prepaid Giveaways
	Prepaid giveaways represent non-inventory samples, which are given away to aid in promotion of the brand and products.
	Prepaid Sponsorship and Endorsement Fees
	Prepaid sponsorship and endorsement fees represent fees paid in connection with Company sponsorships of certain events and trade shows as well as prepaid athlete endorsement fees, which are expensed over the period the fees are earned. A significant amount of the Company’s promotional expenses results from payments under endorsement and sponsorship contracts. Accounting treatment for endorsement and sponsorship payments is based upon specific contract provisions. Generally, endorsement and sponsorship payments are expensed straight-line over the term of the contract after giving recognition to periodic performance compliance provisions of the contract. Prepayments made under the contracts are included in either current or long-term prepaid expenses depending on the performance period for which the prepayment applies.
	Prepaid Stock Compensation
	Prepaid stock compensation represents amounts paid with stock for future contractual benefits to be received. The Company amortizes these contractual benefits over the life of the contracts using the straight-line method.
	Prepaid Expenses
	Prepaid expenses consist of various payments that the Company has made in advance for goods or services to be received in the future. These prepaid expenses include legal retainers, print advertising, insurance and service contracts requiring up-front payments.
	Property and Equipment
	Property and equipment are stated at cost and depreciated to their estimated residual value over their estimated useful lives. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are relieved from the accounts and the resulting gains or losses are included in the Statements of Operations. Repairs and maintenance costs are expensed as incurred. Depreciation is provided using the straight-line method for all property and equipment. We review our property and equipment for impairment when events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. We use an estimate of future undiscounted net cash flows of the related assets or groups of assets over their remaining lives in measuring whether the assets are recoverable. An impairment loss is calculated by determining the difference between the carrying values and the estimated fair values of these assets. We did not consider any of our property and equipment to be impaired during the six months ended June 30, 2014 or 2013.
	Intangible Assets
	Definite-lived intangible assets are amortized over their related useful lives, using a straight-line basis consistent with the underlying expected future cash flows related to the specific intangible asset. Intangible assets are reviewed for impairment whenever events or changes in circumstances exist that indicate the carrying amount of an asset may not be recoverable. When indicators of impairment exist, an estimate of undiscounted net cash flows is used in measuring whether the carrying amount of the asset or related asset group is recoverable. Measurement of the amount of impairment, if any, is based upon the difference between the asset's carrying value and estimated fair value. Fair value is determined through various valuation techniques, including market and income approaches as considered necessary. See Note 15 for further disclosure of intangible assets.
	Accrued Liabilities
	Accrued liabilities consist of amounts estimated by management for future liability payments that relate to the current accounting period. Management reviews these estimates periodically to determine their reasonableness and fair presentation.
	Debt
	The Company defines short term debt as any debt payment due less than one year from the date of the financial statements. Long term debt is defined as any debt payment due more than one year from the date of the financial statements. Refer to Note 6 for further disclosure of debt liabilities.
	Derivatives
	Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in equity instruments and warrants granted, and measurement of their fair value. In determining the appropriate fair value, the Company uses Black-Scholes or lattice option-valuation models. In assessing the convertible equity instruments, management determines if the convertible equity instrument is conventional convertible equity and further if the beneficial conversion feature requires separate measurement.
	Once derivative instruments are determined, they are adjusted to reflect fair value at the end of each reporting period. Any increase or decrease in the fair value is recorded in results of operations as an adjustment to fair value of derivatives. In addition, the fair value of freestanding derivative instruments such as warrants, are also valued using a Black-Scholes or lattice option-pricing model. Once a derivative liability ceases to exist any remaining fair value is reclassified to additional paid-in capital if redeemed or through earnings if forfeited or expired.
	Fair Value of Financial Instruments
	The Company measures assets and liabilities at fair value based on an expected exit price which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.
	The following are the hierarchical levels of inputs to measure fair value:
		⋅	Level 1: Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
		⋅	Level 2: Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.
		⋅	Level 3: Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.
	The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
	The Company’s financial instruments consisted primarily of accounts receivable, accounts payable, accrued liabilities, and notes payable. The Company’s notes payable approximate fair value based upon current borrowing rates available to the Company for debt with similar maturities. The carrying amounts of the Company’s financial instruments generally approximated their fair values as of June 30, 2014 and December 31, 2013, respectively, due to the short-term nature of these instruments.
	Stock-Based Compensation
	Generally, all forms of stock-based compensation, including stock option grants, warrants and restricted stock grants and stock appreciation rights are measured at their fair value on the awards’ grant date, based on estimated number of awards that are ultimately expected to vest. Share-based compensation awards issued to non- employees for services rendered are recorded at either the fair value of the services rendered or the fair value of the stock-based compensation, whichever is more readily determinable.
	Revenue Recognition
	The Company derives revenue primarily from sale of products. The Company records revenue when all of the following have occurred: (1) persuasive evidence of an arrangement exists, (2) product has been shipped or delivered, (3) the sales price to the customer is fixed or determinable, and (4) collectability is reasonably assured.
	Depending on individual customer agreements, sales are recognized either upon shipment of products to customers or upon delivery. For all Canadian sales, which represent 3% of total sales, recognition occurs upon shipment.
	The Company records sales allowances and discounts as a direct reduction of sales. The Company grants volume incentive rebates to certain customers based on contractually agreed upon percentages once certain thresholds have been met. These volume incentive rebates are recorded as a direct reduction to sales.
	The Company has determined that customer advertising related credits are accounted for based on the guidance of ASC No. 605-50-55 (“Revenue Recognition” – Customer Payments and Incentives), which indicates that, absent evidence of benefit to the vendor, appropriate treatment requires netting these types of payments against revenues and not expensing as advertising expense.
	Advertising and Promotion
	Advertising and promotion expenses include digital and print advertising, trade show events, athletic endorsements and sponsorships, and promotional giveaways. Advertising expenses are recognized in the month that the advertising appears while costs associated with trade show events are expensed when the event occurs. For major trade shows, the expenses are recognized within the calendar year over the period in which we recognize revenue associated with sales generated at the trade show. Costs related to promotional giveaways are expensed when the product is either given out at a promotional event or shipped to the customer.
	A significant amount of the Company’s promotional expenses results from payments under endorsement and sponsorship contracts. Accounting treatment for endorsement and sponsorship payments is based upon specific contract provisions. Generally, endorsement payments are expensed straight-line over the term of the contract after giving recognition to periodic performance compliance provisions of the contract. Prepayments made under the contracts are included in either current or long-term prepaid expenses depending on the period for which the prepayment applies.
	Some of the contracts provide for contingent payments to endorsers or athletes based upon specific achievement in their sports (e.g. winning a championship). The Company records expense for these payments when the endorser achieves the specific achievement.
	Income Taxes
	Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Beginning with the adoption of Financial Accounting Standards Board (“FASB”) Interpretation No. 48, Accounting for Uncertainty in Income Taxes, (included in FASB ASC Subtopic 740-10, Income Taxes — Overall), the Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely to be realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.
	The Company records interest and penalties related to unrecognized tax benefits in income tax expense. There were no interest or penalties related to unrecognized tax benefits for the three and six months ended June 30, 2014 and 2013.
	Foreign Currency
	MusclePharm began operations in Canada in April 2012. The Canadian Dollar was determined to be the functional currency as the majority of the transactions related to the day to day operations of the business are in Canadian Dollars. At the end of the period, the financial results of the Canadian operation are translated into the U.S. Dollar, which is the reporting currency, and added to the U.S. operations for consolidated company financial results. The revenue and expense items are translated using the average rate for the month and the assets and liabilities at the month end of rate. Transactions that have completed the accounting cycle and resulted in a gain or loss related to translation are recorded in realized gain or loss due to foreign currency translation under other income and expense on the income statement. Transactions that have not completed their accounting cycle but appear to have gain or loss due to the translation process are recorded as unrealized gain or loss due to translation and recorded as Accumulated other comprehensive income (loss) in the equity section on the balance sheet until such date the accounting cycle of the transaction is complete and the actual realized gain or loss is recognized.

Composition_of_Certain_Financi

Composition of Certain Financial Statement Captions	6 Months Ended
	Jun. 30, 2014
Composition of Certain Financial Statement Captions Abstract [Abstract]	'
Composition of Certain Financial Statement Captions [Text Block]	'
	Note 3: Composition of Certain Financial Statement Captions
	Accounts Receivable
	Accounts receivable, net of allowance consisted of the following at June 30, 2014 and December 31, 2013:
		As of			As of
		June 30, 2014			December 31, 2013
	Accounts receivable	$	19,849,929		$	14,830,487
	Less: allowance for discounts		-511,066			-1,060,000
	Less: allowance for doubtful accounts		-141,319			-29,307
	Accounts receivable – net	$	19,197,544		$	13,741,180
	Inventory
	Inventory, net consisted of the following at June 30, 2014 and December 31, 2013:
		June 30, 2014			December 31, 2013
	Raw materials inventory	$	970,538		$	-
	Work in process inventory		170,843			-
	Finished goods inventory		18,756,934			16,001,515
	Inventory reserve		-128,959			-229,147
	Total inventory - net	$	19,769,356		$	15,772,368
	Finished goods inventory purchased from third party manufacturers as of June 30, 2014 and December 31, 2013 was $18,693,505 and $16,001,515, respectively. Any damaged packaging is returned to the manufacturer for replacement.
	Prepaid Expenses
	Prepaid expenses consisted of the following at June 30, 2014 and December 31, 2013:
		As of			As of
		June 30, 2014			December 31, 2013
	Prepaid advertising and promotion	$	700,707		$	760,740
	Prepaid inventory		385,679			-
	Prepaid insurance		263,632			280,878
	Prepaid professional services		226,120			74,730
	Prepaid director fees		116,000			-
	Prepaid research & development fees		84,221			22,500
	Prepaid license fees		77,141			90,623
	Prepaid software license fees		40,743			86,205
	Prepaid support agreements		36,697			3,499
	Prepaid – other		58,657			16,043
		$	1,989,597		$	1,335,218
	Other Current Assets
	Other current assets consisted of the following at June 30, 2014 and December 31, 2013:
		As of			As of
		June 30, 2014			December 31, 2013
	Vendor rebate receivable	$	119,467		$	-
	Other receivable from Cocrystal Pharma, Inc.		209,396			-
	Other current assets		4,377			40,805
		$	333,240		$	40,805
	Property and Equipment
	Property and equipment consisted of the following at June 30, 2014 and December 31, 2013:
		As of June 30, 2014			As of December 31, 2013			Estimated Useful Life
	Furniture, fixtures and equipment	$	3,173,284		$	1,849,462		From 3 to 5 years
	Leasehold improvements		2,189,963			619,159		From 20 to 182 months
	Manufacturing and lab equipment		1,231,251			-		From 2 to 20 years
	Vehicles		444,065			442,300		From 2 to 5 years
	Displays		33,683			33,683		5 years
	Website		15,975			11,462		3 years
	Construction in process		1,128,588			1,018,509
	Total		8,216,809			3,974,575
	Less: Accumulated depreciation and amortization		-1,995,548			-1,360,991
		$	6,221,261		$	2,613,584
	Other Assets
	Other assets consisted of the following at June 30, 2014 and December 31, 2013:
		As of			As of
		June 30, 2014			December 31, 2013
	Security deposit	$	108,394		$	85,419
	Long-term portion of prepaid assets		71,238			58,810
		$	179,632		$	144,229
	Accrued Liabilities
	Accrued liabilities consisted of the following at June 30, 2014 and December 31, 2013:
	As of			As of
	June 30, 2014			December 31, 2013
Accrued payables	$	2,606,779		$	487,415
Employee compensation and benefits		1,717,265			1,137,681
Capital leases		77,327			26,653
Customer deposits		67,747			265,652
Accrued taxes		25,832			71,771
Other		32,135			63,929
	$	4,527,085		$	2,053,101
Other Long-Term Liabilities
Other long-term liabilities consisted of the following at June 30, 2014 and December 31, 2013:
	As of			As of
	June 30, 2014			December 31, 2013
Customer deposit	$	250,000		$	-
Long-term portion of capital lease liability		116,378			54,639
	$	366,378		$	54,639
Sales and Discounts
Sales for the three and six months ended June 30, 2014 and 2013 were as follows:
	Three Months Ended June 30,							Six Months Ended June 30,
	2014				2013			2014			2013
Sales	$	51,828,561			$	28,515,483		$	108,533,847		$	53,439,519
Discounts and returns		-5,088,574				-3,035,424			-11,584,406			-5,398,293
Sales - Net	$	46,739,987			$	25,480,059		$	96,949,441		$	48,041,226
Discounts as a percent of gross sales		10	%			11	%		11	%		10	%
The Company has an informal seven day right of return for products. There were nominal returns for the three and six months ended June 30, 2014 and 2013.
The Company offers various discounts and sales allowances for volume rebate programs, product promotions, early payment remittances, and other discounts and allowances. The Company accounts for sales discounts and allowances over the period they are earned. Because of the inherent uncertainty surrounding volume rebate programs and product promotions that are based on sales thresholds, actual results could generate liabilities greater or less than the amounts estimated and recorded.
Cost of Sales
Cost of sales for MusclePharm and MusclePharm Canada represent costs directly related to the production, manufacturing and freight of the Company’s products purchased from third party manufacturers. For products produced by Biozone, cost of sales consists of costs for raw material, direct labor, freight expenses, and other supply and equipment rental expenses used to manufacture products.
The Company mainly ships customer orders from our distribution center in Franklin, Tennessee. The facility is operated with the Company’s equipment and employees, and all inventory is owned by the Company. Shipments to customers from our distribution center are recorded as a component of cost of sales. The Company also utilizes a manufacturer in New York to manufacture one of the Company’s products. These orders are typically large and heavy, and are drop shipped directly to our customers at the time of order. Costs associated with these shipments are recorded in cost of sales.
The Company ships Canadian customer orders from our Canadian warehouse and records freight in cost of sales.
The Company ships Biozone products from our manufacturing facility in Pittsburg, California and records freight in cost of sales.

Concentrations

Concentrations	6 Months Ended
	Jun. 30, 2014
Risks and Uncertainties [Abstract]	'
Concentration Risk Disclosure [Text Block]	'
	Note 4: Concentrations
	Accounts Receivable
	At June 30, 2014 and December 31, 2013, the Company had the following concentrations of accounts receivable with significant customers:
	Customer	As of June 30, 2014			As of December 31, 2013
	A		10	%		16	%
	B		10	%		*	%
	C		*	%		24	%
	Bodybuilding.com		*	%		14	%
	* Less than 10% of total accounts receivable
	Revenue
	The Company had the following concentrations of revenues with significant customers:
		Three Months Ended June 30,
	Customer	2014			2013
	Bodybuilding.com		15	%		25	%
	B		10	%		*	%
	C		*	%		11	%
		Six Months Ended June 30,
	Customer	2014			2013
	Bodybuilding.com		15	%		29	%
	B		10	%		11	%
	C		*	%		*	%
	* Less than 10% of gross sales
	Vendors
	The Company uses four non-affiliated principal manufacturers for the components of our products. We have a manufacturing agreement in place with our primary manufacturer to support our growth and ensure consistency in production and quality. The agreement ensures products are manufactured to the Company’s specifications and the manufacturer will bear the costs of any recalled product due to defective manufacturing. The Company had the following concentration of purchases from product vendors:
		Three Months Ended June 30,
	Vendor	2014			2013
	A		47	%		70	%
	B		50	%		30	%
		Six Months Ended June 30,
	Vendor	2014			2013
	A		50	%		82	%
	B		47	%		18	%

Financial_Instruments

Financial Instruments	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	Note 5: Financial Instruments
	The following table is a summary of financial assets and liabilities:
		As of June 30,		As of December 31,
		2014		2013
	Assets
	Debt securities – FUSE convertible notes (Level 2)	$	-	$	259,715
	Derivative instruments – FUSE warrants (Level 2)		-		119,248
			-		378,963
	Liabilities
	Derivative liabilities - Series D shares (Level 2)	$	-	$	1,147,330
	On April 2, 2014, the Company entered into a security purchase agreement and sold the Fuse convertible note and warrants for an aggregate purchase price of $215,000.
	Also on April 2, 2014 the remaining outstanding shares of Series D preferred stock were converted into common shares thereby eliminating the remaining derivative liability for the embedded conversion option as of that date.

Debt

Debt	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	Note 6: Debt
	Debt consists of the following:
		As of June 30, 2014		As of December 31, 2013
	Notes payable	$	45,600	$	59,600
	Revolving line of credit		-		2,500,000
	Auto loan - secured		-		2,902
	Total debt		45,600		2,562,502
	Less: current portion		-45,600		-2,562,502
	Long term debt	$	-	$	-
	Notes Payable
	Notes payable consisted of the following activity and terms:
	Balance – December 31, 2013	$	59,600
	Principal repayments		-14,000
	Balance – June 30, 2014	$	45,600
	Debt in default of $45,600 and $59,600 at June 30, 2014 and December 31, 2013, respectively, is included as a component of short-term debt. Debt in default is related to certain convertible notes issued in 2012 and prior where the notes were never converted to common stock or principal repaid. The Company is in the process of contacting the note holders and negotiating settlement of the notes.
	Revolving Line of Credit
	On December 24, 2013, the Company entered into a revolving line of credit with U.S. Bank, N.A. in the amount of $2,500,000. The line of credit matures on September 15, 2014 and accrues interest at prime plus 2%, which is payable monthly. The note is secured by a $2,500,000 savings account held at U.S. Bank, N.A. and disclosed as restricted cash in the Consolidated Balance Sheets as of December 31, 2013. On May 12, 2014, the Company repaid the outstanding balance of the line of credit with the restricted cash balance that was securing the debt, and terminated the line of credit agreement. The line of credit will not be available for further borrowing.
	Vehicle Loan
	Vehicle loan account consisted of the following activity and terms:
	Balance - December 31, 2013	$	2,902
	Principal repayments		-2,902
	Balance – June 30, 2014	$	-
	As of December 31, 2013, the interest rate associated with this loan was 6.99%. The three final monthly payments of $1,008 per were paid in first quarter 2014.

Derivative_Liabilities

Derivative Liabilities	6 Months Ended
	Jun. 30, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Derivatives and Fair Value [Text Block]	'
	Note 7: Derivative Liabilities
	The Company identified conversion features embedded within Series D Preferred Stock issued in January 2013. The Company has determined that the features associated with the embedded conversion option should be accounted for at fair value as a derivative liability as the Company could not determine if a sufficient number of shares would be available to settle all transactions.
	The fair value of the conversion feature is summarized as follows:
	Derivative liability - December 31, 2013		1,147,330
	Fair value mark to market adjustment for equity instruments		-373,944
	Conversion instruments exercise		-773,386
	Derivative liability – June 30, 2014	$	-
	The Company recorded the day one value of derivative contracts associated with the Series D preferred stock issuance against gross proceeds raised, and expensed immediately the remaining value of the derivative as it exceeded the gross proceeds of the offering. The Company recorded a derivative expense of $0 and $96,913 for the six months ended June 30, 2014 and 2013, respectively.
	On April 2, 2014, the remaining outstanding shares of Series D preferred stock were converted into common shares thereby eliminating the remaining derivative liability for the embedded conversion option as of that date. Of the derivative liability that was eliminated, $773,254 was reclassified to Additional paid-in capital in our Consolidated Balance Sheets.

Restricted_Stock_Units

Restricted Stock Units	6 Months Ended
	Jun. 30, 2014
Schedule Of Share Based Compensation Restricted Stock and Restricted Stock Units [Abstract]	'
Compensation and Employee Benefit Plans [Text Block]	'
	Note 8: Restricted Stock Units
	In November 2012, the Company granted 129,413 restricted stock units to certain executives. Each restricted stock unit represents a contingent right to receive one share of the Company’s common stock upon vesting. The value of this award at the grant date was $449,900 and will be amortized over the vesting periods such that each tranche of restricted stock units will be fully amortized at the date of vesting. The restricted stock units vest as follows: 43,137 on January 1, 2013  43,138 shares on January 1, 2014, and 43,138 shares on December 1, 2014. As of June 30, 2014, 86,275 restricted stock units have vested and the unamortized portion of this award is $75,600.
	In June 2013, the Company approved a restricted stock award to certain key employees, officers and directors for 1,550,000 shares. The shares were issued upon the award’s approval with ownership rights conveyed upon vesting. The value of this award at the grant date was $17,065,500. Of these shares, the Company estimates that 1,500,200 shares will fully vest for a total value of $16,517,202. This amount will be amortized over the vesting periods such that each tranche’s estimated shares of restricted stock will be fully amortized at the dates of vesting. The award vests in two tranches with 17% vesting December 31, 2013 and the remaining 83% vesting December 31, 2015 with the exception of certain executives under employment agreements that terminate prior to December 31, 2015. These awards will be amortized over the remaining term of their employment agreements. As of June 30, 2014, 263,500 shares have vested and the unamortized portion of this award is $9,412,449.
	In December 2013, the Company granted the independent members of the Board of Directors a restricted stock grant of 19,364 shares as part of the annual director’s compensation plan. The awarded shares were issued upon the award’s approval with ownership rights to be conveyed upon vesting. The value of this award at the grant date was $152,000, and will be amortized over the vesting periods. The restricted stock award will vest in three equal tranches on July 1, 2014, July 1, 2015, and July 1, 2016. As of June 30, 2014, no shares have vested and the unamortized portion of the awards was $101,328.
	On March 17, 2014, the Company granted the independent members of the Board of Directors a restricted stock grant of 48,856 shares as part of the annual director’s compensation plan. The awarded shares were issued upon the award’s approval with ownership rights to be conveyed upon vesting. The value of this award at the grant date was $320,007, and will be amortized over the service period, which is January 1 – December 31, 2014. The restricted stock award will vest in three equal tranches on March 17, 2014, March 17, 2015, and March 17, 2016. As of June 30 2014, 16,284 shares have vested and the unamortized portion of the awards is $160,438.
	On May 6, 2014, the Company granted restricted stock awards to certain employees under the June 2013 employee stock grant plan and who joined the Company after the initial employee stock awards in June 2013. The awarded shares were issued upon the award’s approval with ownership rights to be conveyed upon vesting. The value of this award on the grant date was $1,137,600, and will amortized over the vesting periods. The restricted award will vest in five equal tranches on December 31, 2014, 2015, 2016, 2017, and 2018.
	Total compensation expense for these awards recognized during the three months ended June 30, 2014 and 2013 was $2,117,332, and $37,389, respectively. For the six months ended June 30, 2014 and 2013 the total compensation expense for these awards was $4,519,767 and $74,367, respectively, and is included in Operating expenses.

Stockholders_Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	Note 9: Stockholders’ Equity
	Series D Convertible Preferred Stock
	In January 2013 the board of directors authorized 1,600,000 shares of Series D convertible preferred stock. Between January 16, 2013 and February 4, 2013, the Company entered into separate subscription agreements with certain investors in connection with the offering, pursuant to which the Company sold an aggregate of 1,500,000 shares of Preferred Stock for aggregate gross proceeds of approximately $12 million. Pursuant to the Certificate of Designation of the Series D Convertible Preferred Stock filed with the Nevada Secretary of State on January 11, 2013 (the “Certificate of Designation”), each share of Preferred Stock is convertible into two shares of common stock, subject to adjustment as set forth in the Certificate of Designation. On April 2, 2014, the remaining 131,500 shares of outstanding Series D convertible preferred stock were converted to 263,000 shares of common stock.
	Common Stock
	During the six months ended June 30, 2014, the Company issued the following common stock:
	Transaction Type		Quantity			Valuation			Range of Value
			(#)			($)			per Share
									($)
	Conversion of Series D preferred stock to common stock			263,000			773,517			2.94
	Executive/Board of Director compensation			60,422			265,325			3.48 – 8.70
	Stock issued for Biozone acquisition			1,200,000			9,840,000			8.2
	Total			1,523,422			10,878,842			2.94 – 8.70
	The fair value of all stock issuances above is based upon either the quoted closing trading price on the date of issuance or the value of derivative instrument at the date of conversion. See Note 14 for further details of the Biozone acquisition.
	Earnings (Loss) Per Share
	Basic net earnings (loss) per share is computed by dividing net income (loss) for the period by the weighted average number of common stock outstanding during each period. Diluted earnings (loss) per share is computed by dividing net income (loss) for the period by the weighted average number of common stock, common stock equivalents and potentially dilutive securities outstanding during each period.
	The Company uses the “treasury stock” method to determine whether there is a dilutive effect of outstanding option and warrant contracts. For the three and six months ended June 30, 2013 the Company reflected net loss and a dilutive net loss, and the effect of considering any common stock equivalents would have been anti-dilutive for the period. Therefore, separate computation of diluted earnings (loss) per share is not presented for the three and six months ended June 30, 2013.
	The Company has the following common stock equivalents as of June 30, 2014 and 2013, respectively:
			As of June 30,
			2014			2013
	Stock options (exercise price – $425/share)			472			670
	Warrants (exercise price – $4 /share)			-			330,000
	Warrants (exercise price - $1,275/share)			89			89
	Employee and director unvested RSUs			1,501,573			86,275
	Total common stock equivalents			1,502,134			417,034
	The following is a reconciliation of the number of shares used in the calculation of basic and diluted earnings per share for the three and six months ended June 30, 2014 and 2013, respectively:
			Three months ended						Six months ended
			June 30,						June 30,
			2014			2013			2014			2013
	Net income (loss)		$	408,328		$	-2,421,808		$	3,144,562		$	-9,783,789
	Weighted average number of common shares outstanding			10,610,022			7,226,849			10,459,522			5,686,323
	Incremental shares from the assumed exercise of dilutive agreements			1,454,100			-			1,404,360			-
	Diluted common shares outstanding			12,064,122			7,226,849			11,863,882			5,686,323
	Earnings (loss) per shares - basic		$	0.04		$	-0.34		$	0.3		$	-1.72
	Earnings (loss) per shares - diluted		$	0.03		$	-0.34		$	0.27		$	-1.72
	Stock Options
	There was no stock option activity for the three or six months ended June 30, 2014. For the three and six months ended June 30, 2013, the Company had forfeitures of 1,177 options.
	Stock Warrants
	A summary of warrant activity for the Company for the six months ended June 30, 2014 is as follows:
			Number of Warrants			Weighted Average Exercise Price
	Outstanding – December 31, 2013			263,089		$	4.43
	Granted			-			-
	Exercised			-263,000			4
	Balance as June 30, 2014			89		$	1,275
	Warrants Outstanding												Warrants Exercisable
		Range of		Number			Weighted Average			Weighted Average			Number		Weighted		Intrinsic Value
		Exercise Prices		Outstanding			Remaining			Exercise Price			Exercisable		Average
							Contractual Life (in								Exercise Price
							years)
	$	1,275			89			1.04		$	1,275			89	$	1,275		-

Commitments_Contingencies_and_

Commitments, Contingencies and Other Matters	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	Note 10: Commitments, Contingencies and Other Matters
	Operating Leases
	The Company leases office and warehouse facilities under operating leases which expire at various dates through 2029. The amounts reflected in the table below are for the aggregate future minimum lease payments under non-cancelable facility operating leases. Under lease agreements that contain escalating rent provisions, lease expense is recorded on a straight-line basis over the lease term. Rent expense for the six months ended June 30, 2014 and 2013 amounted to $632,882 and $298,887, respectively.
	As of June 30, 2014, future minimum lease payments are as follows:
	Years Ending December 31,
	2014 (remaining 6 months)	$	618,426
	2015		1,087,030
	2016		884,061
	2017		841,118
	2018		838,246
	Thereafter		3,519,391
	Total minimum lease payments	$	7,788,272
	Capital Leases
	The Company leases manufacturing and warehouse equipment under capital leases which expire at various dates through 2017. As of June 30, 2014, the Company had $233,426 in leased assets classified as Furniture, fixtures, and equipment and Manufacturing and lab equipment under Property and equipment in the Consolidated Balance Sheets. The accumulated depreciation on leased assets as of June 30, 2014 was $14,075. Short term capital lease liabilities of $77,327 are included as a component of current liabilities, and the long-term capital lease liabilities of $116,378 are included as a component of long term liabilities in our Consolidated Balance Sheets.
	As of June 30, 2014 and December 31, 2013, the Company had an outstanding balance on capital leases of $193,705 and $81,292, respectively. The amounts reflected in the table below are for the aggregate future minimum lease payments under equipment lease agreements.
	As of June 30, 2014, future minimum lease payments are as follows:
	Years Ending December 31,
	2014 (remaining 6 months)	$	45,661
	2015		91,321
	2016		79,472
	2017		5,898
	Total minimum lease payments		222,352
	Less amounts representing interest		-28,647
	Present value of minimum lease payments	$	193,705
	Contingencies
	For all legal proceedings, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies.
	The Company and its subsidiaries are involved in litigation matters and claims in the normal course of business. In the past, the Company and its subsidiaries have litigated these matters. The Company expects it or its subsidiaries will be involved in legal proceedings in the future. These existing and any future legal actions may harm the Company’s business. Litigation could severely disrupt or shut down the business operations or strategic partners of the Company’s subsidiaries, which in turn would significantly harm ongoing relations with them and cause the Company to lose revenues. The cost associated with legal proceedings are typically high, relatively unpredictable and not completely within the Company’s control. These costs may be materially higher than expected, which could adversely affect the Company’s operating results and lead to volatility in the price of its common stock. Whether or not determined in the Company’s favor or ultimately settled, litigation diverts managerial, technical, legal and financial resources from the Company’s business operations. Furthermore, an adverse decision in any of these legal actions could subject the Company to significant liabilities, lost revenue, negatively impact the Company’s stock price or its business and consolidated financial position, results of operations or cash flows.
	Additionally, as a manufacturer of nutritional supplements and other consumer products that are ingested by consumers, the Company may be subject to various product liability claims. Although we have not had any material claims to date, it is possible that current and future product liability claims could have a material adverse effect on our business or financial condition, results of operations or cash flows. The Company currently maintains product liability insurance with a deductible/retention of $10,000 per claim with an aggregate cap on retained loss of $20,000,000. At June 30, 2014 the Company had not recorded any accruals for product liability claims.
	See Part II, Item I of Form 10Q for further discussion of legal proceedings that the Company is party to.
	Sponsorship and Endorsement Contract Liabilities
	The Company has various non-cancelable endorsement and sponsorship agreements with terms expiring through 2018. The total value of outstanding payments as of June 30, 2014 was $37,102,417. The total outstanding payments are as follows:
	Outstanding Payments	2014		2015		2016		2017		2018		Total
	Endorsement	$	3,730,750	$	8,280,834	$	6,490,833	$	6,600,000	$	3,500,000	$	28,602,417
	Sponsorship		2,357,500		4,905,000		1,137,500		100,000		-		8,500,000
	Total	$	6,088,250	$	13,185,834	$	7,628,333	$	6,700,000	$	3,500,000	$	37,102,417
	SEC Investigation
	In July 2013, the Company received a formal order of investigation of the Company from the Denver Regional Office of the Securities and Exchange Commission. As a result of that formal order, the Company is conducting a review of its internal controls, disclosures of related party transactions, settlements of claims including share issuance, executive compensation, and disclosure of perquisites for the periods of 2010, 2011, and 2012. There can be no assurance that these are the only subject matters of concern, what the nature or amounts in question will be, or that these are the only periods under review. As of June 30, 2014 and the date of this report, there have been no changes in the status of the investigation. See Note 16.

Defined_Contribution_Plan

Defined Contribution Plan	6 Months Ended
	Jun. 30, 2014
Compensation and Retirement Disclosure [Abstract]	'
Pension and Other Postretirement Benefits Disclosure [Text Block]	'
	Note 11: Defined Contribution Plan
	The Company established a 401(k) Plan (the “401(k) Plan”) for eligible employees of the Company. Generally, all employees of the Company who are at least twenty-one years of age and who have completed six months of service are eligible to participate in the 401(k) Plan. The 401(k) Plan is a defined contribution plan that provides that participants may make voluntary salary deferral contributions, on a pretax basis, of up to $17,500 for 2014 (subject to make-up contributions) in the form of voluntary payroll deductions. The Company may make discretionary contributions. During the six months ended June 30, 2014 and 2013 the Company’s matching contribution was $148,745 and $28,530, respectively.

Related_Party_Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	Note 12: Related Party Transactions
	Ryan DeLuca, the Chief Executive Officer of Bodybuilding.com, is the brother of Jeremy DeLuca, MusclePharm’s EVP, MusclePharm Brand and Global Business Development. The Company maintained a business relationship with Bodybuilding.com prior to hiring Mr. DeLuca. The Company does not offer preferential pricing of our products to Bodybuilding.com based on these relationships. Sales of products to Bodybuilding.com were $7,276,542 and $6,933,056, respectively, for the three months ended June 30, 2014 and 2013; and $15,499,998 and $14,953,845 for the six months ended June 30, 2014 and 2013, respectively. Bodybuilding.com owed the Company approximately $1,720,719 and $2,051,265 in trade receivables as of June 30, 2014 and December 31, 2013, respectively. The Company purchased marketing services from Bodybuilding.com during the three and six months ended June 30, 2014 in the amount of $338,877 and $688,885, respectively.
	The Company leases our office and warehouse facility in Hamilton, Ontario, Canada from 2017275 Ontario Inc., which is a company owned by Renzo Passaretti, VP and General Manager of MusclePharm Canada Enterprises Corp, our wholly owned Canadian subsidiary. For the three and six months ended June 30, 2014 we paid rent of $22,951 and $41,015, respectively and for the three and six months ended June 30, 2013, we paid rent of $19,211 and $38,713, respectively. The lease expires March 31, 2016.
	On October 16, 2013, the Company entered into an Office Lease Agreement with Frost Real Estate Holdings, LLC, a Florida limited liability company owned by Dr. Phillip Frost, one of our significant shareholders. Pursuant to the lease, the Company rents 1,437 square feet of office space for an initial term of three years, with an option to renew the lease for an additional three year term. For the three and six months ended June 30, 2014, we paid rent of $15,438 and $26,828, respectively.
	During the six months ended June 30, 2014, the Company purchased split dollar life insurance policies on certain key executives. These policies provide a split of 50% of the death benefit proceeds to the Company and 50% to the officer’s designated beneficiaries.

Endorsement_Agreement

Endorsement Agreement	6 Months Ended
	Jun. 30, 2014
Endorsement Agreement [Abstract]	'
Endorsement Agreement [Text Block]	'
	Note 13: Endorsement Agreement
	On July 26, 2013, the Company entered into an Endorsement Licensing and Co-Branding Agreement by and among, the Company, Arnold Schwarzenegger, Marine MP, LLC, and Fitness Publications, Inc. Under the terms of the Agreement, Mr. Arnold Schwarzenegger will co-develop a special Arnold Schwarzenegger product line and will be co-marketed under Mr. Schwarzenegger’s name and likeness.
	In connection with this agreement, the Company also issued Marine MP, LLC fully vested restricted shares of common stock. As of June 30, 2014 and December 31, 2013, the amount of unamortized stock compensation expense related to this agreement was $5,889,000 and $7,300,800, respectively. The shares are being amortized over the original three year term of the agreement. The current and non-current portions of this unamortized stock compensation are included as a component of Prepaid Stock Compensation in the Consolidated Balance Sheets.

Biozone_Acquisition

Biozone Acquisition	6 Months Ended
	Jun. 30, 2014
Business Combinations [Abstract]	'
Business Combination Disclosure [Text Block]	'
	Note 14: Biozone Acquisition
	On January 2, 2014, the Company completed its acquisition of BioZone Pharmaceuticals, Inc. (“BioZone”) for $9,840,000 in MusclePharm common stock.
	The base purchase price under the asset purchase agreement was 1.2 million shares of the Company’s common stock of which 600,000 shares were placed into escrow for a period of nine months to cover indemnification obligations and which shares are also subject to repurchase from the escrow for $10.00 per share in cash during the nine-month escrow period. The remaining 600,000 non-escrowed shares were issued to Biozone upon closing and are subject to a lockup agreement which permits private sales (subject to the lockup and certain leak out provisions). The total consideration was $9,840,000 in common stock based on the stock price as of January 2, 2014. As of June 30, 2014 and the date of this report, the Company is still evaluating the extent to which there will be adjustments against the purchase price of the Biozone assets and liabilities as a result of certain claims that the Company may assert against Biozone pursuant to the indemnification provision under the APA and the 580 Garcia Lease indemnity agreement.
	The Biozone acquisition is considered an acquisition of a business and was accounted for in accordance with accounting guidance for business combinations. The acquired assets and liabilities have been recognized at their estimated fair value, and the purchase price has been allocated to the tangible and intangible assets acquired and liabilities assumed. MusclePharm contracted a third party valuation firm to determine the fair value at the date of purchase of all identifiable tangible and intangible assets purchased in the acquisition. Based upon the fair values acquired, the purchase price allocation is as follows:
	Purchase Price Allocation
	Net Tangible Assets
	Property & equipment		$	1,859,066
	Receivables			806,212
	Inventory			840,999
	Other assets			577,453
	Factoring payable			-795,031
	Trade payables			-327,038
	Equipment leases			-122,766
	Employee compensation liability			-78,134
	Other liabilities			-76,423
	Total net tangible assets acquired			2,684,338
	Identified Intangible Assets
	Patents		$	5,869,874
	Trademarks			656,160
	Customer lists			629,607
	Domain name			21
	Total identified intangible assets acquired			7,155,662
	Total purchase price		$	9,840,000
	Receivables
	The Company acquired various receivables as part of the asset acquisition of Biozone. The table below reflects the estimated fair value and the contractual value of the receivables as of the transaction date. As of the date of the acquisition the Company determined that none of the receivables were uncollectible.
	Receivables		Estimated Fair			Contractual
			Value			Value
	Trade receivables		$	806,212		$	807,294
	Factoring receivable			150,702			151,016
	Asset sale receivable			399,814			400,000
	Unaudited Pro Forma Income Statement
	The accompanying consolidated statements of operations include the results of the Biozone Acquisition from the acquisition date of January 2, 2014. The Company has determined that there were no significant transactions during the one day which is not presented in the accompanying consolidated statement of operations for the six months ended June 30, 2014 and has therefore not presented the pro forma effects of the acquisition for this period. The unaudited pro forma effects of the acquisition on the results of operations as if the acquisition had been completed on January 1, 2013 for the three and six months ended June 30, 2013 is as follows:
	Three Months Ended June 30, 2013
									Combined
						BioZone			Before Pro							MusclePharm
			MusclePharm			Pharmaceuticals			Forma			Pro Forma				Corp.
			Corp.			Inc.			Adjustments			Adjustments				Pro Forma
	Sales - net		$	25,480,059		$	1,801,600		$	27,281,659		$	-			$	27,281,659
	Net loss			-2,421,808			-708,484			-3,130,292			-119,093	(a)			-3,249,385
	Net loss per share – basic and diluted		$	-0.34			-			-			-			$	-0.45
	Weighted average number of common shares used in per share calculations – basic and diluted			7,226,849			-			-			-				7,226,849
	Six Months Ended June 30, 2013
										Combined
							BioZone			Before Pro							MusclePharm
		MusclePharm					Pharmaceuticals			Forma			Pro Forma				Corp.
		Corp.					Inc.			Adjustments			Adjustments				Pro Forma
	Sales - net			$	48,041,226		$	3,677,131		$	51,718,357		$	-			$	51,718,357
	Net loss				-9,783,789			-1,820,351			-11,604,140			-247,400	(a)			-11,851,540
	Net loss per share – basic and diluted			$	-1.72			-			-			-			$	-2.08
	Weighted average number of common shares used in per share calculations – basic and diluted				5,686,323			-			-			-				5,686,323
		(a)	Pro forma adjustment to eliminate historical seller depreciation expense and record depreciation and amortization expense resulting from the assets acquired.
	The above unaudited pro forma results include adjustments for depreciation of property and equipment and amortization of acquired intangible assets. The unaudited pro forma information as presented above is for informational purposes only and is not necessarily indicative of results of operations that would have been achieved if the acquisition had taken place at the date identified.

Intangible_Assets

Intangible Assets	6 Months Ended
	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Assets Disclosure [Text Block]	'
	Note 15: Intangible Assets
	Intangible assets consist of the following:
		As of June 30, 2014						Weighted
								average
		Gross Assets		Accumulated		Net Assets			amortization
				Amortization					period (years)
	Amortized intangible assets
	Patents	$	5,922,374	$	-456,547	$	5,465,827			8.25
	Trademarks		691,160		-69,281		621,879			7.02
	Customer relationships		629,607		-52,467		577,140			5.51
			7,243,141		-578,295		6,664,846
	Indefinite lived intangible assets
	Domain name		67,686		-		67,686			-
			67,686		-		67,686
	Total intangible assets	$	7,310,827	$	-578,295	$	6,732,532
	Amortization expense for the three months ended June 30, 2014 and 2013 was $293,113 and zero, respectively, and for the six months ended June 30, 2014 and 2013 was $578,295 and zero, respectively. Amortization expense is included in Operating expenses in the Consolidated Statement of Operations.
	As of June 30, 2014, the estimated future amortization expense of intangible assets is as follows:
	2014 (remaining 6 months)	$	550,097
	2015		1,106,314
	2016		999,955
	2017		926,090
	2018		902,187
	Thereafter		2,180,203
	Total amortization expense	$	6,664,846

Insurance_Recovery

Insurance Recovery	6 Months Ended
	Jun. 30, 2014
Insurance [Abstract]	'
Insurance Disclosure [Text Block]	'
	Note 16: Insurance Recovery
	During the quarter ended June 30, 2014, the Company received confirmation from its insurance carrier that legal fees and expenses incurred by the Company in the course of complying with SEC subpoenas and information requests as part of the ongoing SEC investigation as more fully described in Note 10 would be eligible for reimbursement under existing insurance policies. Upon receiving this confirmation, the Company determined it was probable, as defined in ASC 450, that certain legal fees and expenses incurred by the Company would be recoverable under these insurance policies and recorded a receivable of $1,342,843 consisting of fees and expenses incurred from January 1, 2014 through June 30, 2014. Of this receivable, $358,671 related to expenses previously recognized in first quarter 2014 as a component of Professional fees in the Consolidated Statements of Operations. For the three and six months ended June 30, 2014, professional fees would have been $1,292,517 and $2,077,090 without giving effect to the insurance recovery receivable.

Subsequent_Events

Subsequent Events	6 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	Note 17: Subsequent Events
	Tiger Woods Endorsement Agreement
	Effective July 1, 2014, the Company entered into an Endorsement Agreement (the “Agreement”) with ETW Corp. Under the terms of the Agreement, Tiger Woods will endorse certain of the Company’s products and use a golf bag during all professional golf play which prominently displays the MusclePharm name and logo.
	In conjunction with this agreement, on July 3, 2014 (“Issuance Date”), the Company issued 446,853 shares of the Company’s restricted common stock to ETW Corp with an aggregate market value of $5,000,000.
	Jonathan Manziel Endorsement Agreement
	Effective July 15, 2014, the Company entered into an Endorsement Agreement (the “Manziel Agreement”) with JMAN2 General III, LP for the services of Jonathan Manziel. Under the terms of the Manziel Agreement, Mr. Manziel will be available to use, evaluate, promote, and advertise MusclePharm products.
	In conjunction with the Manziel Agreement, the Company issued to JMAN2 General III, LP warrants to purchase 100,000 shares of MusclePharm common stock at an exercise price of $11.90 per share. These warrants vest ratably over a period of 24 months beginning August 15, 2014.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Consolidation, Policy [Policy Text Block]	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of MusclePharm Corporation and its wholly-owned subsidiaries MusclePharm Canada Enterprises Corp (“MusclePharm Canada”) and Biozone Laboratories, Inc. (“Biozone”). MusclePharm Canada began operations in April 2012 and Biozone was acquired in January 2014. All intercompany accounts and transactions have been eliminated upon consolidation
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The accounting estimates and assumptions that require management’s most significant, difficult, and subjective judgment include the recognition and measurement of allowance for doubtful accounts, inventory reserve, derivatives, and sales discounts and allowances reserve among others. Actual results experienced by the Company may differ from management’s estimates.
Risks and Uncertainties [Policy Text Block]	'
	Risks and Uncertainties
	The Company operates in an industry that is subject to rapid change and intense competition. The Company’s operations will be subject to significant risk and uncertainties including financial, operational, technological, regulatory, industry adverse publicity and other risks, including the potential risk of business failure.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board ("FASB") amended the existing accounting standards for revenue recognition. The amendments are based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. MusclePharm is required to adopt the amendments in the first quarter of 2017. Early adoption is not permitted. The amendments may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of initial application. MusclePharm is currently evaluating the impact of these amendments and the transition alternatives on its Consolidated Financial Statements
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash and Cash Equivalents
	The Company considers all highly liquid instruments purchased with an original or remaining maturity of three months or less at the date of purchase to be cash equivalents At June 30, 2014 and December 31, 2013, respectively, the Company had no cash equivalents.
	The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its primary financial institution. The cash balance at times may exceed federally insured limits, and at June 30, 2014 we had one bank account that exceeded the federally insured limit, and at December 31,2013 we had two bank accounts that exceeded the federally insured limit.
Accounts Receivable and Allowance For Doubtful Accounts [Policy Text Block]	'
	Accounts Receivable and Allowance for Doubtful Accounts
	Accounts receivable represents trade obligations from customers that are subject to normal trade collection terms. The Company’s finance department monitors the status of customer receivables and takes actions to collect past due balances as necessary. The Company periodically evaluates the collectability of its accounts receivable and considers the need to establish an allowance for doubtful accounts based upon historical collection experience and specific customer information. Accordingly, the actual amounts could vary from the recorded allowances. There is also a review of customer discounts at the period end and an accrual made for discounts earned but not yet utilized by period end.
	Management performs ongoing evaluations of the Company’s customers’ financial condition and generally does not require collateral. Some international customers are required to pay for their orders in advance of shipment. Management reviews accounts receivable quarterly and reduces the carrying amount by a valuation allowance that reflects management’s best estimate of amounts that may not be collectible. Allowances, if any, for uncollectible accounts receivable are determined based upon the aging of accounts receivable, changes in customer credit worthiness, general market and economic conditions, and historical experience. Bad debt expense recognized as a result of our valuation allowance is classified under Selling, general and administrative expense in the Consolidated Statement of Operations.
	The Company does not charge interest on past due receivables. Receivables are determined to be past due based on the payment terms of the original invoices.
Inventory, Policy [Policy Text Block]	'
	Inventory
	Inventory is valued at the lower of cost or market value. The cost of product inventory for MusclePharm and MusclePharm Canada is computed using actual cost on a First-In First-Out basis, and the cost of inventory for Biozone is computed using an average cost basis. Adjustments to reduce the cost of inventory to its net realizable value are made, if required, and estimates are made for obsolescence, excess or slow-moving inventories, non-conforming inventories, and expired inventory.
Prepaid Giveways [Policy Text Block]	'
	Prepaid Giveaways
	Prepaid giveaways represent non-inventory samples, which are given away to aid in promotion of the brand and products.
Prepaid Sponsorship Fees [Policy Text Block]	'
	Prepaid Sponsorship and Endorsement Fees
	Prepaid sponsorship and endorsement fees represent fees paid in connection with Company sponsorships of certain events and trade shows as well as prepaid athlete endorsement fees, which are expensed over the period the fees are earned. A significant amount of the Company’s promotional expenses results from payments under endorsement and sponsorship contracts. Accounting treatment for endorsement and sponsorship payments is based upon specific contract provisions. Generally, endorsement and sponsorship payments are expensed straight-line over the term of the contract after giving recognition to periodic performance compliance provisions of the contract. Prepayments made under the contracts are included in either current or long-term prepaid expenses depending on the performance period for which the prepayment applies.
Compensation Related Costs, Policy [Policy Text Block]	'
	Prepaid Stock Compensation
	Prepaid stock compensation represents amounts paid with stock for future contractual benefits to be received. The Company amortizes these contractual benefits over the life of the contracts using the straight-line method.
Prepaid Expenses [Policy Text Block]	'
	Prepaid Expenses
	Prepaid expenses consist of various payments that the Company has made in advance for goods or services to be received in the future. These prepaid expenses include legal retainers, print advertising, insurance and service contracts requiring up-front payments.
Property, Plant and Equipment, Policy [Policy Text Block]	'
	Property and Equipment
	Property and equipment are stated at cost and depreciated to their estimated residual value over their estimated useful lives. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are relieved from the accounts and the resulting gains or losses are included in the Statements of Operations. Repairs and maintenance costs are expensed as incurred. Depreciation is provided using the straight-line method for all property and equipment. We review our property and equipment for impairment when events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. We use an estimate of future undiscounted net cash flows of the related assets or groups of assets over their remaining lives in measuring whether the assets are recoverable. An impairment loss is calculated by determining the difference between the carrying values and the estimated fair values of these assets. We did not consider any of our property and equipment to be impaired during the six months ended June 30, 2014 or 2013.
Goodwill and Intangible Assets, Policy [Policy Text Block]	'
	Intangible Assets
	Definite-lived intangible assets are amortized over their related useful lives, using a straight-line basis consistent with the underlying expected future cash flows related to the specific intangible asset. Intangible assets are reviewed for impairment whenever events or changes in circumstances exist that indicate the carrying amount of an asset may not be recoverable. When indicators of impairment exist, an estimate of undiscounted net cash flows is used in measuring whether the carrying amount of the asset or related asset group is recoverable. Measurement of the amount of impairment, if any, is based upon the difference between the asset's carrying value and estimated fair value. Fair value is determined through various valuation techniques, including market and income approaches as considered necessary. See Note 15 for further disclosure of intangible assets.
Accrued Liabilities [Policy Text Block]	'
	Accrued Liabilities
	Accrued liabilities consist of amounts estimated by management for future liability payments that relate to the current accounting period. Management reviews these estimates periodically to determine their reasonableness and fair presentation
Debt, Policy [Policy Text Block]	'
	Debt
	The Company defines short term debt as any debt payment due less than one year from the date of the financial statements. Long term debt is defined as any debt payment due more than one year from the date of the financial statements. Refer to Note 6 for further disclosure of debt liabilities
Derivatives, Policy [Policy Text Block]	'
	Derivatives
	Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in equity instruments and warrants granted, and measurement of their fair value. In determining the appropriate fair value, the Company uses Black-Scholes or lattice option-valuation models. In assessing the convertible equity instruments, management determines if the convertible equity instrument is conventional convertible equity and further if the beneficial conversion feature requires separate measurement.
	Once derivative instruments are determined, they are adjusted to reflect fair value at the end of each reporting period. Any increase or decrease in the fair value is recorded in results of operations as an adjustment to fair value of derivatives. In addition, the fair value of freestanding derivative instruments such as warrants, are also valued using a Black-Scholes or lattice option-pricing model. Once a derivative liability ceases to exist any remaining fair value is reclassified to additional paid-in capital if redeemed or through earnings if forfeited or expired.
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Fair Value of Financial Instruments
	The Company measures assets and liabilities at fair value based on an expected exit price which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.
	The following are the hierarchical levels of inputs to measure fair value:
		·	Level 1: Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
		·	Level 2: Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.
		·	Level 3: Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.
	The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
	The Company’s financial instruments consisted primarily of accounts receivable, accounts payable, accrued liabilities, and notes payable. The Company’s notes payable approximate fair value based upon current borrowing rates available to the Company for debt with similar maturities. The carrying amounts of the Company’s financial instruments generally approximated their fair values as of June 30, 2014 and December 31, 2013, respectively, due to the short-term nature of these instruments.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-Based Compensation
	Generally, all forms of stock-based compensation, including stock option grants, warrants and restricted stock grants and stock appreciation rights are measured at their fair value on the awards’ grant date, based on estimated number of awards that are ultimately expected to vest. Share-based compensation awards issued to non- employees for services rendered are recorded at either the fair value of the services rendered or the fair value of the stock-based compensation, whichever is more readily determinable
Revenue Recognition Accounting Policy, Gross and Net Revenue Disclosure [Policy Text Block]	'
	Revenue Recognition
	The Company derives revenue primarily from sale of products. The Company records revenue when all of the following have occurred: (1) persuasive evidence of an arrangement exists, (2) product has been shipped or delivered, (3) the sales price to the customer is fixed or determinable, and (4) collectability is reasonably assured.
	Depending on individual customer agreements, sales are recognized either upon shipment of products to customers or upon delivery. For all Canadian sales, which represent 3% of total sales, recognition occurs upon shipment.
	The Company records sales allowances and discounts as a direct reduction of sales. The Company grants volume incentive rebates to certain customers based on contractually agreed upon percentages once certain thresholds have been met. These volume incentive rebates are recorded as a direct reduction to sales.
	The Company has determined that customer advertising related credits are accounted for based on the guidance of ASC No. 605-50-55 (“Revenue Recognition” – Customer Payments and Incentives), which indicates that, absent evidence of benefit to the vendor, appropriate treatment requires netting these types of payments against revenues and not expensing as advertising expense.
Advertising Costs, Policy [Policy Text Block]	'
	Advertising and Promotion
	Advertising and promotion expenses include digital and print advertising, trade show events, athletic endorsements and sponsorships, and promotional giveaways. Advertising expenses are recognized in the month that the advertising appears while costs associated with trade show events are expensed when the event occurs. For major trade shows, the expenses are recognized within the calendar year over the period in which we recognize revenue associated with sales generated at the trade show. Costs related to promotional giveaways are expensed when the product is either given out at a promotional event or shipped to the customer.
	A significant amount of the Company’s promotional expenses results from payments under endorsement and sponsorship contracts. Accounting treatment for endorsement and sponsorship payments is based upon specific contract provisions. Generally, endorsement payments are expensed straight-line over the term of the contract after giving recognition to periodic performance compliance provisions of the contract. Prepayments made under the contracts are included in either current or long-term prepaid expenses depending on the period for which the prepayment applies.
	Some of the contracts provide for contingent payments to endorsers or athletes based upon specific achievement in their sports (e.g. winning a championship). The Company records expense for these payments when the endorser achieves the specific achievement.
Income Tax, Policy [Policy Text Block]	'
	Income Taxes
	Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Beginning with the adoption of Financial Accounting Standards Board (“FASB”) Interpretation No. 48, Accounting for Uncertainty in Income Taxes, (included in FASB ASC Subtopic 740-10, Income Taxes — Overall), the Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely to be realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.
	The Company records interest and penalties related to unrecognized tax benefits in income tax expense. There were no interest or penalties related to unrecognized tax benefits for the three and six months ended June 30, 2014 and 2013.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	'
	Foreign Currency
	MusclePharm began operations in Canada in April 2012. The Canadian Dollar was determined to be the functional currency as the majority of the transactions related to the day to day operations of the business are in Canadian Dollars. At the end of the period, the financial results of the Canadian operation are translated into the U.S. Dollar, which is the reporting currency, and added to the U.S. operations for consolidated company financial results. The revenue and expense items are translated using the average rate for the month and the assets and liabilities at the month end of rate. Transactions that have completed the accounting cycle and resulted in a gain or loss related to translation are recorded in realized gain or loss due to foreign currency translation under other income and expense on the income statement. Transactions that have not completed their accounting cycle but appear to have gain or loss due to the translation process are recorded as unrealized gain or loss due to translation and recorded as Accumulated other comprehensive income (loss) in the equity section on the balance sheet until such date the accounting cycle of the transaction is complete and the actual realized gain or loss is recognized.

Concentrations_Tables

Concentrations (Tables)	6 Months Ended
	Jun. 30, 2014
Accounts Receivable [Member]	'
Concentration Risk [Line Items]	'
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	'
	At June 30, 2014 and December 31, 2013, the Company had the following concentrations of accounts receivable with significant customers:
	Customer	As of June 30, 2014			As of December 31, 2013
	A		10	%		16	%
	B		10	%		*	%
	C		*	%		24	%
	Bodybuilding.com		*	%		14	%
	* Less than 10% of total accounts receivable
Sales Revenue, Net [Member]	'
Concentration Risk [Line Items]	'
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	'
	The Company had the following concentrations of revenues with significant customers:
		Three Months Ended June 30,
	Customer	2014			2013
	Bodybuilding.com		15	%		25	%
	B		10	%		*	%
	C		*	%		11	%
		Six Months Ended June 30,
	Customer	2014			2013
	Bodybuilding.com		15	%		29	%
	B		10	%		11	%
	C		*	%		*	%
	* Less than 10% of gross sales
Cost of Goods, Total [Member]	'
Concentration Risk [Line Items]	'
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	'
	The Company had the following concentration of purchases from product vendors:
		Three Months Ended June 30,
	Vendor	2014			2013
	A		47	%		70	%
	B		50	%		30	%
		Six Months Ended June 30,
	Vendor	2014			2013
	A		50	%		82	%
	B		47	%		18	%

Composition_of_Certain_Financi1

Composition of Certain Financial Statement Captions (Tables)	6 Months Ended
	Jun. 30, 2014
Composition of Certain Financial Statement Captions Abstract [Abstract]	'
Schedule Of Accounts Receivable [Table Text Block]	'
	Accounts receivable, net of allowance consisted of the following at June 30, 2014 and December 31, 2013:
		As of			As of
		June 30, 2014			December 31, 2013
	Accounts receivable	$	19,849,929		$	14,830,487
	Less: allowance for discounts		-511,066			-1,060,000
	Less: allowance for doubtful accounts		-141,319			-29,307
	Accounts receivable – net	$	19,197,544		$	13,741,180
Schedule of Inventory, Current [Table Text Block]	'
	Inventory, net consisted of the following at June 30, 2014 and December 31, 2013:
		June 30, 2014			December 31, 2013
	Raw materials inventory	$	970,538		$	-
	Work in process inventory		170,843			-
	Finished goods inventory		18,756,934			16,001,515
	Inventory reserve		-128,959			-229,147
	Total inventory - net	$	19,769,356		$	15,772,368
Schedule of Prepaid Expense Current [Table Text Block]	'
	Prepaid expenses consisted of the following at June 30, 2014 and December 31, 2013:
		As of			As of
		June 30, 2014			December 31, 2013
	Prepaid advertising and promotion	$	700,707		$	760,740
	Prepaid inventory		385,679			-
	Prepaid insurance		263,632			280,878
	Prepaid professional services		226,120			74,730
	Prepaid director fees		116,000			-
	Prepaid research & development fees		84,221			22,500
	Prepaid license fees		77,141			90,623
	Prepaid software license fees		40,743			86,205
	Prepaid support agreements		36,697			3,499
	Prepaid – other		58,657			16,043
		$	1,989,597		$	1,335,218
Schedule of Other Current Assets [Table Text Block]	'
	Other current assets consisted of the following at June 30, 2014 and December 31, 2013:
		As of			As of
		June 30, 2014			December 31, 2013
	Vendor rebate receivable	$	119,467		$	-
	Other receivable from Cocrystal Pharma, Inc.		209,396			-
	Other current assets		4,377			40,805
		$	333,240		$	40,805
Property, Plant and Equipment [Table Text Block]	'
	Property and equipment consisted of the following at June 30, 2014 and December 31, 2013:
		As of June 30, 2014			As of December 31, 2013			Estimated Useful Life
	Furniture, fixtures and equipment	$	3,173,284		$	1,849,462		From 3 to 5 years
	Leasehold improvements		2,189,963			619,159		From 20 to 182 months
	Manufacturing and lab equipment		1,231,251			-		From 2 to 20 years
	Vehicles		444,065			442,300		From 2 to 5 years
	Displays		33,683			33,683		5 years
	Website		15,975			11,462		3 years
	Construction in process		1,128,588			1,018,509
	Total		8,216,809			3,974,575
	Less: Accumulated depreciation and amortization		-1,995,548			-1,360,991
		$	6,221,261		$	2,613,584
Schedule of Other Assets [Table Text Block]	'
	Other assets consisted of the following at June 30, 2014 and December 31, 2013:
		As of			As of
		June 30, 2014			December 31, 2013
	Security deposit	$	108,394		$	85,419
	Long-term portion of prepaid assets		71,238			58,810
		$	179,632		$	144,229
Schedule of Accrued Liabilities [Table Text Block]	'
	Accrued liabilities consisted of the following at June 30, 2014 and December 31, 2013:
		As of			As of
		June 30, 2014			December 31, 2013
	Accrued payables	$	2,606,779		$	487,415
	Employee compensation and benefits		1,717,265			1,137,681
	Capital leases		77,327			26,653
	Customer deposits		67,747			265,652
	Accrued taxes		25,832			71,771
	Other		32,135			63,929
		$	4,527,085		$	2,053,101
Other Noncurrent Liabilities [Table Text Block]	'
	Other long-term liabilities consisted of the following at June 30, 2014 and December 31, 2013:
		As of			As of
		June 30, 2014			December 31, 2013
	Customer deposit	$	250,000		$	-
	Long-term portion of capital lease liability		116,378			54,639
		$	366,378		$	54,639
Schedule Of Sales [Table Text Block]	'
	Sales for the three and six months ended June 30, 2014 and 2013 were as follows:
		Three Months Ended June 30,							Six Months Ended June 30,
		2014				2013			2014			2013
	Sales	$	51,828,561			$	28,515,483		$	108,533,847		$	53,439,519
	Discounts and returns		-5,088,574				-3,035,424			-11,584,406			-5,398,293
	Sales - Net	$	46,739,987			$	25,480,059		$	96,949,441		$	48,041,226
	Discounts as a percent of gross sales		10	%			11	%		11	%		10	%

Financial_Instruments_Tables

Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	'
	The following table is a summary of financial assets and liabilities:
		As of June 30,		As of December 31,
		2014		2013
	Assets
	Debt securities – FUSE convertible notes (Level 2)	$	-	$	259,715
	Derivative instruments – FUSE warrants (Level 2)		-		119,248
			-		378,963
	Liabilities
	Derivative liabilities - Series D shares (Level 2)	$	-	$	1,147,330

Debt_Tables

Debt (Tables)	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Schedule Of Long Term Debt [Table Text Block]	'
	Debt consists of the following:
		As of June 30, 2014		As of December 31, 2013
	Notes payable	$	45,600	$	59,600
	Revolving line of credit		-		2,500,000
	Auto loan - secured		-		2,902
	Total debt		45,600		2,562,502
	Less: current portion		-45,600		-2,562,502
	Long term debt	$	-	$	-
Schedule Of Convertible Debt Activity And Terms [Table Text Block]	'
	Notes payable consisted of the following activity and terms:
	Balance – December 31, 2013	$	59,600
	Principal repayments		-14,000
	Balance – June 30, 2014	$	45,600
Schedule Of Auto Loan Activity and Terms [Table Text Block]	'
	Vehicle loan account consisted of the following activity and terms:
	Balance - December 31, 2013	$	2,902
	Principal repayments		-2,902
	Balance – June 30, 2014	$	-

Derivative_Liabilities_Tables

Derivative Liabilities (Tables)	6 Months Ended
	Jun. 30, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Schedule Of Fair Value Of Derivative Instruments Conversion Feature [Table Text Block]	'
	The fair value of the conversion feature is summarized as follows:
	Derivative liability - December 31, 2013		1,147,330
	Fair value mark to market adjustment for equity instruments		-373,944
	Conversion instruments exercise		-773,386
	Derivative liability – June 30, 2014	$	-

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity Note [Abstract]	'
Schedule of Stockholders Equity [Table Text Block]	'
	During the six months ended June 30, 2014, the Company issued the following common stock:
	Transaction Type		Quantity			Valuation			Range of Value
			(#)			($)			per Share
									($)
	Conversion of Series D preferred stock to common stock			263,000			773,517			2.94
	Executive/Board of Director compensation			60,422			265,325			3.48 – 8.70
	Stock issued for Biozone acquisition			1,200,000			9,840,000			8.2
	Total			1,523,422			10,878,842			2.94 – 8.70
Schedule Of Common Stock Equivalents [Table Text Block]	'
	The Company has the following common stock equivalents as of June 30, 2014 and 2013, respectively:
			As of June 30,
			2014			2013
	Stock options (exercise price – $425/share)			472			670
	Warrants (exercise price – $4 /share)			-			330,000
	Warrants (exercise price - $1,275/share)			89			89
	Employee and director unvested RSUs			1,501,573			86,275
	Total common stock equivalents			1,502,134			417,034
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
	The following is a reconciliation of the number of shares used in the calculation of basic and diluted earnings per share for the three and six months ended June 30, 2014 and 2013, respectively:
			Three months ended						Six months ended
			June 30,						June 30,
			2014			2013			2014			2013
	Net income (loss)		$	408,328		$	-2,421,808		$	3,144,562		$	-9,783,789
	Weighted average number of common shares outstanding			10,610,022			7,226,849			10,459,522			5,686,323
	Incremental shares from the assumed exercise of dilutive agreements			1,454,100			-			1,404,360			-
	Diluted common shares outstanding			12,064,122			7,226,849			11,863,882			5,686,323
	Earnings (loss) per shares - basic		$	0.04		$	-0.34		$	0.3		$	-1.72
	Earnings (loss) per shares - diluted		$	0.03		$	-0.34		$	0.27		$	-1.72
Schedule Of Warrants Activity [Table Text Block]	'
	A summary of warrant activity for the Company for the six months ended June 30, 2014 is as follows:
			Number of Warrants			Weighted Average Exercise Price
	Outstanding – December 31, 2013			263,089		$	4.43
	Granted			-			-
	Exercised			-263,000			4
	Balance as June 30, 2014			89		$	1,275
	Warrants Outstanding												Warrants Exercisable
		Range of		Number			Weighted Average			Weighted Average			Number		Weighted		Intrinsic Value
		Exercise Prices		Outstanding			Remaining			Exercise Price			Exercisable		Average
							Contractual Life (in								Exercise Price
							years)
	$	1,275			89			1.04		$	1,275			89	$	1,275		-

Committments_Contingencies_and

Committments, Contingencies and Other Matters (Tables)	6 Months Ended
	Jun. 30, 2014
Operating Leased Assets [Line Items]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	As of June 30, 2014, future minimum lease payments are as follows:
	Years Ending December 31,
	2014 (remaining 6 months)	$	618,426
	2015		1,087,030
	2016		884,061
	2017		841,118
	2018		838,246
	Thereafter		3,519,391
	Total minimum lease payments	$	7,788,272
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	'
	As of June 30, 2014, future minimum lease payments are as follows:
	Years Ending December 31,
	2014 (remaining 6 months)	$	45,661
	2015		91,321
	2016		79,472
	2017		5,898
	Total minimum lease payments		222,352
	Less amounts representing interest		-28,647
	Present value of minimum lease payments	$	193,705
Sponsorship and Endorsement Contract Liabilities [Member]	'
Operating Leased Assets [Line Items]	'
Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block]	'
	The total value of outstanding payments as of June 30, 2014 was $37,102,417. The total outstanding payments are as follows:
	Outstanding Payments	2014		2015		2016		2017		2018		Total
	Endorsement	$	3,730,750	$	8,280,834	$	6,490,833	$	6,600,000	$	3,500,000	$	28,602,417
	Sponsorship		2,357,500		4,905,000		1,137,500		100,000		-		8,500,000
	Total	$	6,088,250	$	13,185,834	$	7,628,333	$	6,700,000	$	3,500,000	$	37,102,417

Biozone_Acquisition_Tables

Biozone Acquisition (Tables)	6 Months Ended
	Jun. 30, 2014
Business Combinations [Abstract]	'
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	'
	Based upon the fair values acquired, the purchase price allocation is as follows:
	Purchase Price Allocation
	Net Tangible Assets
	Property & equipment		$	1,859,066
	Receivables			806,212
	Inventory			840,999
	Other assets			577,453
	Factoring payable			-795,031
	Trade payables			-327,038
	Equipment leases			-122,766
	Employee compensation liability			-78,134
	Other liabilities			-76,423
	Total net tangible assets acquired			2,684,338
	Identified Intangible Assets
	Patents		$	5,869,874
	Trademarks			656,160
	Customer lists			629,607
	Domain name			21
	Total identified intangible assets acquired			7,155,662
	Total purchase price		$	9,840,000
Schedule of Business Combination Acquired Receivables [Table Text Block]	'
	As of the date of the acquisition the Company determined that none of the receivables were uncollectible.
	Receivables		Estimated Fair			Contractual
			Value			Value
	Trade receivables		$	806,212		$	807,294
	Factoring receivable			150,702			151,016
	Asset sale receivable			399,814			400,000
Business Acquisition, Pro Forma Information [Table Text Block]	'
	The unaudited pro forma effects of the acquisition on the results of operations as if the acquisition had been completed on January 1, 2013 for the three and six months ended June 30, 2013 is as follows:
	Three Months Ended June 30, 2013
									Combined
						BioZone			Before Pro							MusclePharm
			MusclePharm			Pharmaceuticals			Forma			Pro Forma				Corp.
			Corp.			Inc.			Adjustments			Adjustments				Pro Forma
	Sales - net		$	25,480,059		$	1,801,600		$	27,281,659		$	-			$	27,281,659
	Net loss			-2,421,808			-708,484			-3,130,292			-119,093	(a)			-3,249,385
	Net loss per share – basic and diluted		$	-0.34			-			-			-			$	-0.45
	Weighted average number of common shares used in per share calculations – basic and diluted			7,226,849			-			-			-				7,226,849
	Six Months Ended June 30, 2013
										Combined
							BioZone			Before Pro							MusclePharm
		MusclePharm					Pharmaceuticals			Forma			Pro Forma				Corp.
		Corp.					Inc.			Adjustments			Adjustments				Pro Forma
	Sales - net			$	48,041,226		$	3,677,131		$	51,718,357		$	-			$	51,718,357
	Net loss				-9,783,789			-1,820,351			-11,604,140			-247,400	(a)			-11,851,540
	Net loss per share – basic and diluted			$	-1.72			-			-			-			$	-2.08
	Weighted average number of common shares used in per share calculations – basic and diluted				5,686,323			-			-			-				5,686,323
		(a)	Pro forma adjustment to eliminate historical seller depreciation expense and record depreciation and amortization expense resulting from the assets acquired.

Intangible_Assets_Tables

Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]	'
	Intangible assets consist of the following:
		As of June 30, 2014						Weighted
								average
		Gross Assets		Accumulated		Net Assets			amortization
				Amortization					period (years)
	Amortized intangible assets
	Patents	$	5,922,374	$	-456,547	$	5,465,827			8.25
	Trademarks		691,160		-69,281		621,879			7.02
	Customer relationships		629,607		-52,467		577,140			5.51
			7,243,141		-578,295		6,664,846
	Indefinite lived intangible assets
	Domain name		67,686		-		67,686			-
			67,686		-		67,686
	Total intangible assets	$	7,310,827	$	-578,295	$	6,732,532
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
	As of June 30, 2014, the estimated future amortization expense of intangible assets is as follows:
	2014 (remaining 6 months)	$	550,097
	2015		1,106,314
	2016		999,955
	2017		926,090
	2018		902,187
	Thereafter		2,180,203
	Total amortization expense	$	6,664,846

Composition_of_Certain_Financi2

Composition of Certain Financial Statement Captions (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Composition Of Certain Financial Statement Captions [Line Items]	'	'
Accounts receivable	$19,849,929	$14,830,487
Less: allowance for discounts	-511,066	-1,060,000
Less: allowance for doubtful accounts	-141,319	-29,307
Accounts receivable - net	$19,197,544	$13,741,180

Composition_of_Certain_Financi3

Composition of Certain Financial Statement Captions (Details 1) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Inventory [Line Items]	'	'
Raw materials inventory	$970,538	$0
Work in process inventory	170,843	0
Finished goods inventory	18,756,934	16,001,515
Inventory reserve	-128,959	-229,147
Total inventory - net	$19,769,356	$15,772,368

Composition_of_Certain_Financi4

Composition of Certain Financial Statement Captions (Details 2) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Composition Of Certain Financial Statement Captions [Line Items]	'	'
Prepaid advertising and promotion	$700,707	$760,740
Prepaid inventory	385,679	0
Prepaid insurance	263,632	280,878
Prepaid professional services	226,120	74,730
Prepaid director fees	116,000	0
Prepaid research & development fees	84,221	22,500
Prepaid license fees	77,141	90,623
Prepaid software license fees	40,743	86,205
Prepaid support agreements	36,697	3,499
Prepaid - other	58,657	16,043
Prepaid Expense, Current	$1,989,597	$1,335,218

Composition_of_Certain_Financi5

Composition of Certain Financial Statement Captions (Details 3) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Composition Of Certain Financial Statement Captions [Line Items]	'	'
Vendor rebate receivable	$119,467	$0
Other receivable from Cocrystal Pharma, Inc.	209,396	0
Other current assets	4,377	40,805
Other Assets, Current	$333,240	$40,805

Composition_of_Certain_Financi6

Composition of Certain Financial Statement Captions (Details 5) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Composition Of Certain Financial Statement Captions [Line Items]	'	'
Security deposit	$108,394	$85,419
Long-term portion of prepaid assets	71,238	58,810
Other Assets, Noncurrent	$179,632	$144,229

Composition_of_Certain_Financi7

Composition of Certain Financial Statement Captions (Details 4) (USD $)	6 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Total	$8,216,809	$3,974,575
Less: Accumulated depreciation and amortization	-1,995,548	-1,360,991
Property, Plant and Equipment, Net	6,221,261	2,613,584
Furniture, Fixtures And Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total	3,173,284	1,849,462
Furniture, Fixtures And Equipment [Member] | Minimum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Estimated Useful Life (in years)	'3 years	'
Furniture, Fixtures And Equipment [Member] | Maximum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Estimated Useful Life (in years)	'5 years	'
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total	2,189,963	619,159
Leasehold Improvements [Member] | Minimum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Estimated Useful Life (in years)	'20 months	'
Leasehold Improvements [Member] | Maximum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Estimated Useful Life (in years)	'182 months	'
Manufacturing and lab equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total	1,231,251	0
Manufacturing and lab equipment [Member] | Minimum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Estimated Useful Life (in years)	'2 years	'
Manufacturing and lab equipment [Member] | Maximum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Estimated Useful Life (in years)	'20 years	'
Vehicles [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total	444,065	442,300
Vehicles [Member] | Minimum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Estimated Useful Life (in years)	'2 years	'
Vehicles [Member] | Maximum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Estimated Useful Life (in years)	'5 years	'
Displays [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total	33,683	33,683
Property, Plant and Equipment, Estimated Useful Life (in years)	'5 years	'
Website [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total	15,975	11,462
Property, Plant and Equipment, Estimated Useful Life (in years)	'3 years	'
Construction in Progress [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total	$1,128,588	$1,018,509

Composition_of_Certain_Financi8

Composition of Certain Financial Statement Captions (Details 6) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Composition Of Certain Financial Statement Captions [Line Items]	'	'
Accrued payables	$2,606,779	$487,415
Employee compensation and benefits	1,717,265	1,137,681
Capital leases	77,327	26,653
Customer deposits	67,747	265,652
Accrued taxes	25,832	71,771
Other	32,135	63,929
Accrued Liabilities, Current	$4,527,085	$2,053,101

Composition_of_Certain_Financi9

Composition of Certain Financial Statement Captions (Details 7) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Composition Of Certain Financial Statement Captions [Line Items]	'	'
Customer deposit	$250,000	$0
Long-term portion of capital lease liability	116,378	54,639
Other Liabilities, Noncurrent	$366,378	$54,639

Recovered_Sheet1

Composition of Certain Financial Statement Captions (Details 8) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Composition Of Certain Financial Statement Captions [Line Items]	'	'	'	'
Sales	$51,828,561	$28,515,483	$108,533,847	$53,439,519
Discounts and returns	-5,088,574	-3,035,424	-11,584,406	-5,398,293
Sales - Net	$46,739,987	$25,480,059	$96,949,441	$48,041,226
Discounts as a percent of gross sales	10.00%	11.00%	11.00%	10.00%

Recovered_Sheet2

Composition of Certain Financial Statement Captions (Details Textual) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Composition Of Certain Financial Statement Captions [Line Items]	'	'
Inventory, Finished Goods, Gross	$18,756,934	$16,001,515
Third Party Manufacturers [Member]	'	'
Composition Of Certain Financial Statement Captions [Line Items]	'	'
Inventory, Finished Goods, Gross	$18,693,505	$16,001,515

Concentrations_Details

Concentrations (Details) (Accounts Receivable [Member])	6 Months Ended		12 Months Ended
	Jun. 30, 2014		Dec. 31, 2013
Customer A [Member]	'		'
Concentration Risk [Line Items]	'		'
Concentration Risk, Percentage	10.00%		16.00%
Customer B [Member]	'		'
Concentration Risk [Line Items]	'		'
Concentration Risk, Percentage	10.00%		0.00%	[1]
Customer C [Member]	'		'
Concentration Risk [Line Items]	'		'
Concentration Risk, Percentage	0.00%	[1]	24.00%
Bodybuilding.com [Member]	'		'
Concentration Risk [Line Items]	'		'
Concentration Risk, Percentage	0.00%	[1]	14.00%
[1]	Less than 10% of total accounts receivable

Concentrations_Details_1

Concentrations (Details 1) (Sales Revenue, Net [Member])	3 Months Ended				6 Months Ended
	Jun. 30, 2014		Jun. 30, 2013		Jun. 30, 2014		Jun. 30, 2013
Bodybuilding.com [Member]	'		'		'		'
Concentration Risk [Line Items]	'		'		'		'
Concentration Risk, Percentage	15.00%		25.00%		15.00%		29.00%
Customer B [Member]	'		'		'		'
Concentration Risk [Line Items]	'		'		'		'
Concentration Risk, Percentage	10.00%		0.00%	[1]	10.00%		11.00%
Customer C [Member]	'		'		'		'
Concentration Risk [Line Items]	'		'		'		'
Concentration Risk, Percentage	0.00%	[1]	11.00%		0.00%	[1]	0.00%	[1]
[1]	Less than 10% of gross sales

Concentrations_Details_2

Concentrations (Details 2) (Cost of Goods, Total [Member])	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Vendor A [Member]	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration Risk, Percentage	47.00%	70.00%	50.00%	82.00%
vendor B [Member]	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration Risk, Percentage	50.00%	30.00%	47.00%	18.00%

Financial_Instruments_Details

Financial Instruments (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Assets	'	'
Debt securities - FUSE convertible notes (Level 2)	$0	$259,715
Derivative instruments - FUSE warrants (Level 2)	0	119,248
Assets, Fair Value Disclosure, Total	0	378,963
Liabilities	'	'
Derivative liabilities - Series D shares (Level 2)	$0	$1,147,330

Financial_Instruments_Details_

Financial Instruments (Details Textual) (USD $)	0 Months Ended
	Apr. 02, 2014
Financial Instruments [Line Items]	'
Sale Of Convertible Notes And Warrants	$215,000

Debt_Details

Debt (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Schedule of Capitalization, Long-term Debt [Line Items]	'	'
Notes payable	$45,600	$59,600
Revolving line of credit	0	2,500,000
Auto loan - secured	0	2,902
Total debt	45,600	2,562,502
Less: current portion	-45,600	-2,562,502
Long term debt	$0	$0

Debt_Details_1

Debt (Details 1) (USD $)	6 Months Ended
	Jun. 30, 2014
Debt Instrument [Line Items]	'
Balance - December 31, 2013	$59,600
Principal repayments	-14,000
Balance - June 30, 2014	$45,600

Debt_Details_2

Debt (Details 2) (USD $)	6 Months Ended
	Jun. 30, 2014
Debt Instrument [Line Items]	'
Balance - December 31, 2013	$2,902
Principal repayments	-2,902
Balance - June 30, 2014	$0

Debt_Details_Textual

Debt (Details Textual) (USD $)	6 Months Ended			3 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013	Dec. 24, 2013	Mar. 31, 2014	Dec. 31, 2013	Jun. 30, 2014
				Notes Payable, Other Payables [Member]	Notes Payable, Other Payables [Member]	U.S. Bank, N.A D Savings Deposits [Member]
Debt Instrument [Line Items]	'	'	'	'	'	'
Debt Default, Short-term Debt, Amount	$45,600	$59,600	'	'	'	'
Line of Credit Facility, Maximum Borrowing Capacity	'	'	2,500,000	'	'	'
Line of Credit Facility, Expiration Date	15-Sep-14	'	'	'	'	'
Line of Credit Facility, Interest Rate Description	'prime plus 2%	'	'	'	'	'
Restricted Cash and Investments, Current, Total	'	'	'	'	'	2,500,000
Debt Instrument, Interest Rate During Period	'	'	'	'	6.99%	'
Debt Instrument, Periodic Payment	'	'	'	$1,008	'	'

Derivative_Liabilities_Details

Derivative Liabilities (Details) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Derivative Liabilities [Line Items]	'	'
Derivative liability - December 31, 2013	$1,147,330	'
Fair value mark to market adjustment for equity instruments	-373,944	'
Conversion instruments exercise	773,386	0
Derivative liability - June 30, 2014	$0	'

Derivative_Liabilities_Details1

Derivative Liabilities (Details Textual) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Apr. 02, 2014
Derivative Liabilities [Line Items]	'	'	'	'	'
Derivative expense	$0	$0	$0	$96,913	'
Embedded Derivative, Fair Value of Embedded Derivative Liability	'	'	'	'	$773,254

Restricted_Stock_Units_Details

Restricted Stock Units (Details Textual) (USD $)

3 Months Ended

6 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

12 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Nov. 30, 2012

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2014

Mar. 17, 2014

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Subsequent Event [Member]

December 31, 2013 [Member]

December 31, 2015 [Member]

Restricted Stock [Member]

Chief Financial Officer [Member]

Chief Financial Officer [Member]

key employees officers and directors [Member]

key employees officers and directors [Member]

key employees officers and directors [Member]

Director [Member]

Director [Member]

Director [Member]

Director [Member]

Subsequent Event [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

December 31, 2015 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Issued For Services (in shares)

'

'

'

'

'

'

'

'

129,413

'

'

'

'

'

'

'

'

Stock Issued During Period, Value, Issued For Services

'

'

'

'

'

'

'

'

$449,900

'

'

'

'

'

'

'

'

Shares Vesting In Next Twelve Months Number

'

'

'

'

'

'

'

'

'

43,137

'

'

'

'

'

'

'

Shares Vesting In Year Two Number

43,138

'

43,138

'

43,138

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period

'

'

'

'

'

'

'

'

'

86,275

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not Yet Recognized

9,412,449

'

9,412,449

'

'

'

'

'

'

75,600

'

'

'

'

160,438

'

101,328

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

'

'

'

'

'

'

'

'

'

'

'

1,550,000

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares

'

'

'

'

'

'

'

'

'

'

'

1,500,200

'

'

16,284

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value

'

'

'

'

'

'

'

'

'

'

'

16,517,202

'

'

'

'

'

Stock Issued During Period, Value, Restricted Stock Award, Gross

'

'

'

'

'

'

'

'

'

'

17,065,500

'

'

320,007

'

152,000

'

Restricted stock agreement grant vesting percentage

'

'

'

'

'

17.00%

83.00%

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares

'

'

'

'

'

'

'

'

'

'

'

'

263,500

'

'

'

'

Share-based Compensation

2,117,332

37,389

4,466,876

74,366

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Restricted Stock Award, Gross

'

'

'

'

'

'

'

'

'

'

'

'

'

48,856

'

19,364

'

Stock Granted, Value, Share-based Compensation, Gross

'

'

'

'

'

'

'

$1,137,600

'

'

'

'

'

'

'

'

'

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	6 Months Ended
	Jun. 30, 2014
Class of Stock [Line Items]	'
Conversion of Series D preferred stock to common stock, Quantity	263,000
Conversion of Series D preferred stock to common stock, Valuation	$773,517
Conversion of Series D preferred stock to common stock, Range Of value per share	$2.94
Executive/Board of Director compensation, Quantity	60,422
Executive/Board of Director compensation, Valuation	265,325
Stock issued for Biozone acquisition, Quantity	1,200,000
Stock issued for Biozone acquisition, Valuation	9,840,000
Stock issued for Biozone acquisition, Range of value per share	$8.20
Total, Quantity	1,523,422
Total, Valuation	$10,878,842
Minimum [Member]	'
Class of Stock [Line Items]	'
Executive/Board of Director compensation, Range of Value per share	$3.48
Total, Range of Value per Share	$2.94
Maximum [Member]	'
Class of Stock [Line Items]	'
Executive/Board of Director compensation, Range of Value per share	$8.70
Total, Range of Value per Share	$8.70

Stockholders_Equity_Details_1

Stockholders' Equity (Details 1)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Class of Stock [Line Items]	'	'
Total common stock equivalents	1,502,134	417,034
Employee Stock Option [Member]	'	'
Class of Stock [Line Items]	'	'
Total common stock equivalents	472	670
Warrant [Member]	'	'
Class of Stock [Line Items]	'	'
Total common stock equivalents	0	330,000
Warrants One [Member]	'	'
Class of Stock [Line Items]	'	'
Total common stock equivalents	89	89
Employee and Director Unvested Shares [Member]	'	'
Class of Stock [Line Items]	'	'
Total common stock equivalents	1,501,573	86,275

Stockholders_Equity_Details_2

Stockholders' Equity (Details 2) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Class of Stock [Line Items]	'	'	'	'
Net income (loss)	$408,328	($2,421,808)	$3,144,562	($9,783,789)
Weighted average number of common shares outstanding (in shares)	10,610,022	7,226,849	10,459,522	5,686,323
Incremental shares from the assumed exercise of dilutive agreements (in shares)	1,454,100	0	1,404,360	0
Diluted common shares outstanding	12,064,122	7,226,849	11,863,882	5,686,323
Earnings (loss) per shares - basic (in dollars per share)	$0.04	($0.34)	$0.30	($1.72)
Earnings (loss) per shares - diluted (in dollars per share)	$0.03	($0.34)	$0.27	($1.72)

Stockholders_Equity_Details_3

Stockholders' Equity (Details 3) (USD $)	6 Months Ended
	Jun. 30, 2014
Class of Stock [Line Items]	'
Number of Warrants, Outstanding Balance (in shares)	263,089
Number of Warrants, Granted (in shares)	0
Number of Warrants, Exercised (in shares)	-263,000
Number of Warrants, Outstanding Balance (in shares)	89
Weighted Average Exercise Price, Balance (in dollars per share)	$4.43
Weighted Average Exercise Price, Granted (in dollars per share)	$0
Weighted Average Exercise Price, Exercised/ (in dollars per share)	$4
Weighted Average Exercise Price, Balance (in dollars per share)	$1,275
Warrant [Member]	'
Class of Stock [Line Items]	'
Weighted Average Exercise Price, Balance (in dollars per share)	$1,275
Warrant Outstanding Number Outstanding	89
Warrants Outstanding, Weighted Average Remaining Contractual Life (in years)	'1 year 14 days
Warrant Outstanding Weighted Average Exercise Price	$1,275
Warrants Exercisable, Numbers Exercisable (in shares)	89
Warrants Exercisable, Weighted Average Exercise Price (in dollars per share)	$1,275
Warrants Exercisable, Intrinsic Value	$0

Stockholders_Equity_Details_Te

Stockholders' Equity (Details Textual) (USD $)	3 Months Ended	6 Months Ended			1 Months Ended
	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Apr. 02, 2014	Feb. 04, 2013	Jun. 30, 2014	Apr. 02, 2014	Dec. 31, 2013	Jan. 31, 2013
				Common Stock [Member]	Series D Convertible Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]
Stockholders Equity Disclosure [Line Items]	'	'	'	'	'	'	'	'	'
Preferred stock, shares authorized	'	'	'	'	'	1,600,000	'	1,600,000	1,600,000
Number Of Shares Sold Under Subscription Agreement	'	'	'	'	1,500,000	'	'	'	'
Proceeds from Issuance of Preferred Stock and Preference Stock	'	$0	$12,000,000	'	$12,000,000	'	'	'	'
Preferred Stock, Shares Outstanding	'	'	'	263,000	'	0	131,500	131,500	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	1,177	'	1,177	'	'	'	'	'	'

Commitments_Contingencies_and_1

Commitments, Contingencies and Other Matters (Details) (USD $)	Jun. 30, 2014
Years Ending December 31,	'
2014 (remaining 6 months)	$618,426
2015	1,087,030
2016	884,061
2017	841,118
2018	838,246
Thereafter	3,519,391
Total minimum lease payments	$7,788,272

Commitments_Contingencies_and_2

Commitments, Contingencies and Other Matters (Details 1) (USD $)	Jun. 30, 2014
Years Ending December 31,	'
2014 (remaining 6 months)	$45,661
2015	91,321
2016	79,472
2017	5,898
Total minimum lease payments	222,352
Less amounts representing interest	-28,647
Present value of minimum lease payments	$193,705

Commitments_Contingencies_and_3

Commitments, Contingencies and Other Matters (Details 2) (Sponsorship and Endorsement Contract Liabilities [Member], USD $)	Jun. 30, 2014
Contractual Obligation, Fiscal Year Maturity [Line Items]	'
2014	$6,088,250
2015	13,185,834
2016	7,628,333
2017	6,700,000
2018	3,500,000
Total	37,102,417
Endorsement [Member]	'
Contractual Obligation, Fiscal Year Maturity [Line Items]	'
2014	3,730,750
2015	8,280,834
2016	6,490,833
2017	6,600,000
2018	3,500,000
Total	28,602,417
Sponsorship [Member]	'
Contractual Obligation, Fiscal Year Maturity [Line Items]	'
2014	2,357,500
2015	4,905,000
2016	1,137,500
2017	100,000
2018	0
Total	$8,500,000

Commitments_Contingencies_and_4

Commitments, Contingencies and Other Matters (Details Textual) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Commitments And Contingency [Line Items]	'	'	'
Operating Lease Expire Term	'2029	'	'
Operating Leases, Rent Expense, Net	$632,882	$298,887	'
Product Liability Insurance Deduction	10,000	'	'
Aggregate Product Liability Retained Loss	20,000,000	'	'
Capital Lease Obligations, Current	77,327	'	'
Capital Lease Obligations, Noncurrent	116,378	'	54,639
Capital Lease Obligations	193,705	'	81,292
Capital Leases, Balance Sheet, Assets by Major Class, Net, Total	233,426	'	'
Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation	14,075	'	'
Capital Lease Expire Term	'2017	'	'
Sponsorship and Endorsement Contract Liabilities [Member]	'	'	'
Commitments And Contingency [Line Items]	'	'	'
Operating Lease Expire Term	'2018	'	'
Contractual Obligation, Total	$37,102,417	'	'

Defined_Contribution_Plan_Deta

Defined Contribution Plan (Details Textual) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Defined Contribution Pension And Other Postretirement Plans Disclosure [Line Items]	'	'
Noncash Contribution Expense	$17,500	'
Defined Contribution Plan, Employer Discretionary Contribution Amount	$148,745	$28,530

Related_Party_Transactions_Det

Related Party Transactions (Details Textual) (USD $)

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Oct. 16, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Bodybuilding.com [Member]

Bodybuilding.com [Member]

Bodybuilding.com [Member]

Bodybuilding.com [Member]

Bodybuilding.com [Member]

Frost Real Estate Holdings, LLC [Member]

Frost Real Estate Holdings, LLC [Member]

Frost Real Estate Holdings, LLC [Member]

VP and General Manager [Member]

VP and General Manager [Member]

VP and General Manager [Member]

VP and General Manager [Member]

sqft

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenue from Related Parties

'

'

$7,276,542

$6,933,056

$15,499,998

$14,953,845

'

'

'

'

'

'

'

'

Due from Related Parties

'

'

1,720,719

'

1,720,719

'

2,051,265

'

'

'

'

'

'

'

Securities Purchase Under Agreement Description

'The Company purchased marketing services from Bodybuilding.com during the three and six months ended June 30, 2014 in the amount of $338,877 and $688,885, respectively.

'

'

'

'

'

'

'

'

'

'

'

'

'

Operating Leases, Rent Expense, Net

$632,882

$298,887

'

'

'

'

'

$15,438

$26,828

'

$22,951

$19,211

$41,015

$38,713

Lease Expiration Date

31-Mar-16

'

'

'

'

'

'

'

'

'

'

'

'

'

Area of Land

'

'

'

'

'

'

'

'

'

1,437

'

'

'

'

Deferred Compensation Arrangements, Overall, Description

'the Company purchased split dollar life insurance policies on certain key executives. These policies provide a split of 50% of the death benefit proceeds to the Company and 50% to the officers designated beneficiaries

'

'

'

'

'

'

'

'

'

'

'

'

'

Endorsement_Agreement_Details_

Endorsement Agreement (Details Textual) (Marine MP LLC [Member], USD $)	Jun. 30, 2014	Dec. 31, 2013
Marine MP LLC [Member]	'	'
Endorsement Agreement Disclosure [Line Items]	'	'
Prepaid Expense	$5,889,000	$7,300,800

Biozone_Acquisition_Details

Biozone Acquisition (Details) (USD $)	6 Months Ended
	Jun. 30, 2014
Net Tangible Assets	'
Property & equipment	$1,859,066
Receivables	806,212
Inventory	840,999
Other assets	577,453
Factoring payable	-795,031
Trade payables	-327,038
Equipment leases	-122,766
Employee compensation liability	-78,134
Other liabilities	-76,423
Total net tangible assets acquired	2,684,338
Intangible assets	'
Total identified intangible assets acquired	7,155,662
Total purchase price	9,840,000
Patents [Member]	'
Intangible assets	'
Total intangible assets	5,869,874
Trademarks [Member]	'
Intangible assets	'
Total intangible assets	656,160
Customer Relationships [Member]	'
Intangible assets	'
Total intangible assets	629,607
Domain name [Member]	'
Intangible assets	'
Total intangible assets	$21

Biozone_Acquisition_Details_1

Biozone Acquisition (Details 1) (USD $)	Jun. 30, 2014
Trade Accounts Receivable [Member]	'
Business Acquisition [Line Items]	'
Fair Value	$806,212
Contractual Value	807,294
Factoring receivable [Member]	'
Business Acquisition [Line Items]	'
Fair Value	150,702
Contractual Value	151,016
Asset sale receivable [Member]	'
Business Acquisition [Line Items]	'
Fair Value	399,814
Contractual Value	$400,000

Biozone_Acquisition_Details_2

Biozone Acquisition (Details 2) (USD $)	3 Months Ended	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2013
Muscle Pharm Corp. Pro Forma [Member]	'	'
Business Acquisition [Line Items]	'	'
Total net revenues	$27,281,659	$51,718,357
Net loss	-3,249,385	-11,851,540
Net loss per share - basic and diluted	($0.45)	($2.08)
Weighted average number of common shares used in per share calculations - basic and diluted	7,226,849	5,686,323
Combined Before Pro Forma Adjustments [Member]	'	'
Business Acquisition [Line Items]	'	'
Total net revenues	27,281,659	51,718,357
Net loss	-3,130,292	-11,604,140
Net loss per share - basic and diluted	$0	$0
Weighted average number of common shares used in per share calculations - basic and diluted	0	0
Pro Forma Adjustments [Member]	'	'
Business Acquisition [Line Items]	'	'
Total net revenues	0	0
Net loss	-119,093	-247,400
Net loss per share - basic and diluted	$0	$0
Weighted average number of common shares used in per share calculations - basic and diluted	0	0
BioZone Pharmaceuticals Inc [Member]	'	'
Business Acquisition [Line Items]	'	'
Total net revenues	1,801,600	3,677,131
Net loss	-708,484	-1,820,351
Net loss per share - basic and diluted	$0	$0
Weighted average number of common shares used in per share calculations - basic and diluted	0	0
Parent Company [Member]	'	'
Business Acquisition [Line Items]	'	'
Total net revenues	25,480,059	48,041,226
Net loss	($2,421,808)	($9,783,789)
Net loss per share - basic and diluted	($0.34)	($1.72)
Weighted average number of common shares used in per share calculations - basic and diluted	7,226,849	5,686,323

Biozone_Acquisition_Details_Te

Biozone Acquisition (Details Textual) (USD $)	6 Months Ended
	Jun. 30, 2014
Business Acquisition [Line Items]	'
Stock Issued During Period, Shares, Acquisitions	1,200,000
Escrow Period	'9 months
Business Acquisition, Share Price	$10
Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Shares Issued	9,840,000
Escrow [Member]	'
Business Acquisition [Line Items]	'
Stock Issued During Period, Shares, Acquisitions	600,000
Non-escrowed [Member]	'
Business Acquisition [Line Items]	'
Stock Issued During Period, Shares, Acquisitions	600,000

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014
			Domain name [Member]	Patents [Member]	Trademarks [Member]	Customer Relationships [Member]
Intangible Assets [Line Items]	'	'	'	'	'	'
Finite-Lived Intangible Assets, Gross	$7,243,141	'	'	$5,922,374	$691,160	$629,607
Indefinite-Lived Intangible Assets (Excluding Goodwill)	67,686	'	67,686	'	'	'
Intangible Assets, Gross (Excluding Goodwill), Total	7,310,827	'	'	'	'	'
Finite-Lived Intangible Assets, Accumulated Amortization	-578,295	'	'	-456,547	-69,281	-52,467
Finite-Lived Intangible Assets, Net, Total	6,664,846	'	'	5,465,827	621,879	577,140
Intangible Assets, Net (Excluding Goodwill), Total	$6,732,532	$155,165	'	'	'	'
Finite-Lived Intangible Asset, Useful Life	'	'	'	'8 years 3 months	'7 years 7 days	'5 years 6 months 4 days

Intangible_Assets_Details_1

Intangible Assets (Details 1) (USD $)	Jun. 30, 2014
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Line Items]	'
2014 (remaining 6 months)	$550,097
2015	1,106,314
2016	999,955
2017	926,090
2018	902,187
Thereafter	2,180,203
Total amortization expense	$6,664,846

Intangible_Assets_Details_Text

Intangible Assets (Details Textual) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Intangible Assets [Line Items]	'	'	'	'
Amortization of Intangible Assets	$293,113	$0	$578,295	$0

Insurance_Recovery_Details_Tex

Insurance Recovery (Details Textual) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2014	Dec. 31, 2013
Insurance Recovery [Line Items]	'	'	'	'
Accounts and Other Receivables, Net, Current	$1,342,843	'	$1,342,843	$0
Professional Fees	$1,292,517	$358,671	$2,077,090	'

Subsequent_Events_Details_Text

Subsequent Events (Details Textual) (Subsequent Event [Member], USD $)	0 Months Ended
	Jul. 03, 2014	Jul. 15, 2014
Subsequent Event [Member]	'	'
Subsequent Event [Line Items]	'	'
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures	$446,853	'
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures	5,000,000	'
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	'	100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	'	$11.90
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'24 months